Title: The global prevalence of female genital mutilation/cutting: A systematic review and meta-
analysis of national, regional, facility and school-based studies.

Short title: Global prevalence of female genital mutilation

Authors: Leen Farouki BA[1], Zeinab El Dirani MSc[1], Sawsan Abdulrahim PhD[2], Christelle Akl
MS[1], Chaza Akik DrPH[1], Stephen J McCall DPhil[1]

Affiliations:

1. Center for Research on Population and Health, Faculty of Health Sciences, American
University of Beirut, Lebanon

2. Department of Health Promotion and Community Health, Faculty of Health Sciences,
American University of Beirut, Lebanon.

Corresponding Author: Stephen J McCall

Email: sm227@aub.edu.lb

Telephone: +961 1 350 000 ext. 4563

Abstract (420/500 words)

Background: Female Genital Mutilation/Cutting (FGM/C) is a non-medical procedure entailing the modification of the external female genitalia. A description of the prevalence and distribution of FGM/C allows the tracking of progress towards ending FGM/C by 2030 (Sustainable Development Goal (SDG) Target 5.3). This systematic review aimed to examine FGM/C prevalence and types, by World Health Organization (WHO) region and country.

Methods: A systematic search using Medical Subject Headings (MeSH) and keywords from 2009 to March 24, 2022 was undertaken in MEDLINE, PubMED, PsycINFO, Web of Science, and Embase to identify studies presenting FGM/C prevalence. Abstract and full-text screening, quality assessment, and data extraction were undertaken by two reviewers. Only nationally representative studies were included in the meta-analysis. Pooled FGM/C prevalence was estimated by random-effects meta-analysis using generalised linear mixed models (GLMM). FGM/C prevalence with 95% confidence intervals (CI), prediction intervals (PI) and FGM/C type were presented separately by women aged 15-49 years and girls aged 0-14 years.

Findings: 161 studies met the inclusion criteria and 28 were included in the meta-analysis, of which 22 were from the WHO African region (AFR), 5 Eastern Mediterranean region (EMR), and 1 South-East Asia (SEAR) region. These studies included data from 397,683 women across 28 countries and 283,437 girls across 23 countries; the pooled prevalence estimate of FGM/C amongst women aged 15-49 years was 38.3% (95% CI: 20.8–59.5%; PI:0.48–98.8%), and 7.25% (95% CI:3.1–16.0%; PI: 0.1-88.9%) amongst girls aged 0-14 years. Amongst included countries, this gave a total estimated prevalence of 86,080,915 women (95%CI: 46,736,701–133,693,929) and 11,982,031 girls with FGM/C (95% CI: 5,123,351–26,476,156). Somalia had the highest FGM/C prevalence amongst women (99.2%) and Mali had the highest amongst girls (72.7%). The most common type of FGM/C amongst women was "flesh removed" (Type I or II) in 19 countries, and "not sewn closed" (Type I, II, or IV) amongst girls in 9 countries. Among repeated nationally representative studies, FGM/C decreased for women and girls in 23 and 24 countries respectively, although in several countries there was a minor decrease (0-3%) or increase in prevalence.

Discussion: In this study, we observed large variation in FGM/C prevalence between countries, and the prevalence appears to be declining in many countries, which is encouraging as it

minimises physical and physiological harm for a future generation of women. This prevalence

estimate is lower than the actual global prevalence of FGM/C due to data gaps, non-comparable

denominators, and unavailable surveys. Yet, considerable policy and community-level

interventions are required in many countries to meet the SDG target 5.3.

Funding: None

Registration: CRD42020186937

Author Summary

Why was this study done?

- FGM/C is an extreme form of gender inequality that violates women's and girls' human rights, and the practice has lifelong health and economic consequences for women and girls.
- Previous studies on prevalence of FGM/C have used repeated nationally representative cross-sectional studies and found that FGM/C is decreasing in many countries.
- This study aimed to provide a baseline prevalence estimate and to understand the data gaps in prevalence required for tracking progress towards the Sustainable Development Goal (SDG) Target 5.3.

What did the researchers do and find?

- This was a systematic review and meta-analysis of all available studies on FGM/C and it provided a thorough overview of studies published on FGM/C prevalence at a national, sub-regional, school, facility, and community level.
- Approximately 100 million girls and women of reproductive age have experienced FGM/C across 28 countries in three WHO regions, with a prevalence of 38% in women and 7% among girls.
- There were large differences between regions and countries; where some countries practiced FGM/C universally, and FGM/C appeared to be decreasing in 23 countries for women and 25 countries for girls.

What do these findings mean?

- Current findings imply that progress towards SDG 5.3 is attainable in some countries, but much work is required in others, including Egypt, Somalia, Sudan, Indonesia, Guinea, and Mali.
- Evaluation of structural or community level policies and interventions in countries that had a decline in FGM/C will be beneficial for countries that have a high prevalence of FGM/C.

94 • The prevalence estimate of this study is accurate of the included countries but is an

95 underestimate of the global prevalence due to gaps in available data across the world,

96 which are important to resolve to understand actual progress towards SDG 5.3.

Introduction

Female Genital Mutilation/Cutting (FGM/C), also referred to as female circumcision is a non-medical procedure that entails the total or partial removal of external female genitalia and other injuries to the female genital organs [1]. The United Nations Sustainable Development Goal (SDG) target 5.3 on gender equality refers to FGM/C as a harmful traditional practice and calls for ending it by 2030 .

While the exact global prevalence of FGM/C is unknown, estimates of FGM/C range from 100-140 million women and girls in African region and the Middle East [2, 3], while UNICEF estimates the global prevalence to be over 200 million women and girls living with FGM/C [1-4]. Nationally representative data show that there is a decline in the prevalence of FMG/C but this is not universal across countries [1, 5, 6]. FGM/C persists due to religious, social, and cultural factors [7]. It is commonly believed to create better marriage prospects because it associates with morality, hygiene, and aesthetics; FGM/C is also believed to curb sexual urges and maintain virginity [8]. However, the procedure has no health benefits; it has resulted in negative health outcomes, including menstrual difficulties, infertility, urinary problems, mental health problems, pregnancy and labour complications severe pain, risk of contracting infections, septicaemia, and even death [9-11]. FGM/C also has economic burden throughout the life course for girls and women [12].

FGM/C is most often performed on girls between infancy and adolescence, and has been classified into four types [13]. Type I (clitoridectomy) involves the partial or total removal of the prepuce and/or the clitoral gland. Type II involves the partial or total removal of the labia minora and clitoral glans without the excision of the labia majora. Type III (infibulation) involves narrowing the vaginal canal by modifying the labia majora and minora and may also include the removal of the clitoral glans. Type IV involves any other non-medical, harmful procedure, such as cauterization, pricking, and scraping [14]. Risks defer by type; the most severe type, Type III, has more serious obstetric risks of FGM/C including infant resuscitation, stillbirth, and neonatal death while Types I and II carry risks of caesarean section or postpartum bleeding [15].

An important aspect of the SDGs is to track progress on ending harmful traditional practices, such as FGM/C. However, to our knowledge, there is no comprehensive review in the literature

that provides estimates of FGM/C globally, by World Health Organization (WHO) region, or

specific countries, which can be used to track improvements towards SDG 5.3. A review of the

prevalence of FGM/C will support efforts to understand the global burden of FGM/C and inform

adequate prevention and intervention efforts, and local and international policies. A review of the

types of FGM/C will contribute similarly by tracking the prevalence of the severity of the

procedure. This systematic review and meta-analysis aimed to examine (1) the prevalence of

FGM/C and (2) the proportion of the different types of FGM/C, amongst girls aged 0-14 years

and women aged 15-49 years old by country and WHO region.

Methods

Search strategy and study selection. In this systematic review and meta-analysis of FGM/C prevalence, separate searches were conducted using MEDLINE, PubMED, PsycINFO, Web of Science, and Embase. Hand searches of the grey literature were conducted through searches of reports from international non-governmental organizations, including UNFPA and UNICEF amongst others, and other Google searches. Hand searches of the bibliographies of relevant systematic reviews were also conducted. Together, these databases provide international and interdisciplinary publications. The search strategy (S1 Methods and Results, S1 Table) was adapted to the format of each database. To present up-to-date data that can be used as a baseline to monitor progress on SDG 5.3 over the last decade, the search was limited to include publications from 2009 until 2020. The search was updated to include publications from 2009 until 2022. The last search in all databases was conducted on March 24th, 2022. For nationally representative studies, the hand searches were conducted to include studies prior to 2009 in a post-hoc analysis to present FGM/C prevalence across time. The MeSH term for FGM/C was used when possible; otherwise, keywords were used, including "Female Genital Mutilation," "Female Genital Alteration," "Female Circumcision," and "Female Genital Cutting". No language restrictions were imposed. The references were imported from each database into EndNote then into systematic review software Distiller SR and duplicates were removed [16].

Study protocol, registration and reporting. The reporting of this study was based on the Preferred Reporting Items for Systematic Review (PRISMA) reporting guidelines (S2 PRISMA Checklist) [17, 18]. The prospectively written study protocol is (S3 Study Protocol) available at: https://osf.io/ema9j/ [19] and was registered with PROSPERO, number CRD42020186937.

Inclusion and exclusion criteria. This systematic review and meta-analysis were part of a larger project on FGM/C prevalence and its determinants [7, 19]. Cohort or cross-sectional studies that reported on FGM/C prevalence at the national level, using representative samples or population-based methods, were included in the systematic review and meta-analysis. Sub-regional, facility, community and school-based studies and studies that used non-population-based methods or non-probability sampling designs, including cross-sectional, cohort designs, were included in the systematic review but not in the meta-analysis. Furthermore, case-series in migrant populations

outside of countries that practice FGM/C were included to understand the scope of the literature

on FGM/C in these countries.

Studies were excluded if they (i) only reported on health outcomes of FGM/C, the attitudes and

knowledge of healthcare providers, economic effects, or perceptions of FGM/C, (ii) only used

qualitative methods, (iii) were systematic reviews (except for referencing), or (iv) were policy

reports, conference proceedings or letters to the editor. If numerous journal articles used the

same data source, e.g. secondary data analysis of international surveys, only the original report

was included. Other than nationally representative studies, if the same data source completed

multiple studies in a given country across time, then the most recent was included. The

supplementary material contains further details on the included and excluded studies (S1

Methods and Results, S1 Text).

Study Screening. Titles and abstracts were screened independently by two reviewers. Articles

selected for full-text review were also screened by two reviewers, independently and in

duplicates. The reasons for exclusion at both the abstract and full-text stages were recorded.

Disagreements between the two reviewers were resolved by discussion and consulting a third

reviewer who verified the eligibility of all included studies. The supplementary material contains

further details on the screening process (S1 Methods and Results).

Data extraction and quality assessment. Data were extracted from included articles using a

structured data extraction form, uploaded into DistillerSR. Data were extracted by one reviewer

and verified by a second reviewer; disagreements were resolved by a third reviewer. Data

included in the final tables were verified against the original publication by a further reviewer.

Items extracted from studies included study characteristics, sampling methods, design, host

country and country of origin, ethnicity, age, age at FGM/C, location of procedure, performer of

FGM/C, FGM/C prevalence, and proportion of the different FGM/C types. The FGM/C

prevalence in each included study was extracted as a proportion or calculated from the numbers

presented. All data items were extracted from the most recent nationally representative studies

(e.g. MICS or DHS), while only prevalence estimates were extracted from the older nationally

representative studies for the post-hoc analysis. Studies were assessed for risk of bias

independently by two reviewers using an adapted tool by Hoy and colleagues (S1 Methods and

Results, S3 Table), which is specific to prevalence studies [20]. This tool includes nine items that

collectively assess the selection bias, representativeness of the sample, validity of the tool, and

appropriateness of the estimate. Each item was scored as low or high risk of bias, and each paper

was given an overall score rated as low, moderate, or high risk of bias.

Data Analysis

Because the literature fell into certain categories, namely nationally representative, sub-regional,

and non-probability samples, data in the present study were grouped similarly. Prevalence

estimates from the different studies were grouped by country, WHO region and study design.

Pooled estimates of FGM/C prevalence were only presented from studies with representative

samples or population-based methods at a national level, and the most recent survey was used in

the meta-analysis. Prevalence estimates were presented separately for women aged 15-49 years

old and girls aged 0-14 years old as most studies collected data for women and girls separately as

defined by these age groups and it was considered inappropriate to pool these groups together

due to a cohort effect [5, 21]. Studies that estimated FGM/C among girls using the number of

women with at least 1 daughter with FGM/C were excluded from the meta-analysis because this

does not provide an estimate of prevalence among all girls aged 0-14 years old. The denominator

of FGM/C type was the total number of women and girls with FGM/C, respectively. In addition,

a post-hoc summary of prevalence estimates of FGM/C for each country were presented across

time for both women and girls.

For the meta-analysis, heterogeneity between studies is usually assessed using the I^2 statistic

[22]. Although high values of I^2 are common in meta-analysis for prevalence studies, prediction

intervals are recommended to be presented as a measure of heterogeneity [23]. The prediction

interval is the range where a proportion from a future study would be expected to be located

within if this study was randomly selected from the same group of studies included in the meta-

analysis [24]. τ^2 values were also presented as a measure of the variance of effect sizes amongst

studies [25]. Using data extracted from survey reports, a random-effects meta-analysis was

conducted to produce a pooled prevalence across all nationally representative studies and across

each WHO region. The random-effects meta-analysis of the pooled prevalence, 95% confidence

intervals (CI) and prediction intervals (PI) were estimated using Generalized Linear Mixed

Models (GLMM) [26] through the 'metaprop' command within the Meta package, version 4.15-

1 [27]. Funnel plots were constructed to inspect visual asymmetry using the funnelR package,

version 0.1.0, which was developed for proportion data (S1 Figure and S2 Figure) [28].

To provide the total number of girls (0-14 years old) and women (15-49 years old) with FGM/C,

the pooled prevalence estimate was extrapolated against the age-specific population total in

2020, which only included countries that were included in the meta-analysis, using the UN

Population Division [29]. All statistical analyses were conducted using R version 4.1.2.

Protocol amendments

The protocol was amended to include studies in any language and to specify the disaggregation

by age group; available at: https://osf.io/xehpa/ (S3 Study Protocol). Other than studies involving

migrants, case series and case-control studies were excluded as prevalence cannot be calculated.

A data driven analysis was conducted to present prevalence of FMG/C across time from national

surveys. A GLMM meta-analysis was used rather than a Freeman-Tukey transformation due to

the limitations of the latter approach [26]. We also provided prediction intervals due to recent

methodological recommendations and we present total number of women and girls with FGM/C

to allow comparison with other global estimates [23].

Ethical approval and role of the funding source

This was a systematic review of published studies, so no ethical approval was required. There

was no funding source for this study.

Results

Out of 2913 records retrieved from database and hand searches, 417 publications were assessed under full-text review. Of these, a total of 161 were included in the systematic review: 28 nationally representative studies were included in the meta-analysis of the prevalence of FGM/C and two were included in the systematic review but not in the meta-analysis; 33 sub-regional studies; and 98 non-population-based studies including 44 on migrant populations (Figure 1). The Indonesia RISKESDAS [30] was not included in the meta-analysis because it did not provide the sample size, and the Pew Research Center survey [31], Eritrea Population and Health Survey [32] and Yemen DHS survey [33] were not included in the meta-analysis of FGM/C prevalence of girls as these surveys had non-comparable denominators.

Nationally representative studies

Of the 30 nationally representative studies, 17 used data from Demographic and Health Surveys (DHS), 10 use data from Multiple Indicator Cluster Surveys (MICS), and three used other population-based surveys (S4 Results: S4 Table). Furthermore, 22 represent the African Region (AFR) [32, 34-54], five represent the Eastern Mediterranean Region (EMR) [33, 55-58], two represent the South-East Asian Region (SEAR) [30, 59], and one represented both EMR and AFR [31]. All national studies reported FGM/C prevalence among the total number of women and girls in surveyed households, except surveys from Liberia (reported on women who have heard of FGM/C) [45], Niger [49], and Uganda [54] that reported only on women, and surveys from Yemen [33], Eritrea [32] and Pew Research Center survey [31] which asked women whether at least one of their daughters had FGM/C. Apart from that of the Pew Research Center, all studies had a low risk of bias and used a cross-sectional design with multi-stage cluster sampling. The Pew Research Center survey had a moderate risk of bias, a cross-sectional design, and used stratified random sampling [31].

The 28 nationally representative studies included in the meta-analysis provided data on women in 28 countries and data on girls in 23 countries. Out of a total of 397,683 women aged 15-49 years in 28 countries, 163,415 women had FGM/C representing a pooled prevalence of 38.3% (CI: 20.8-59.5%; PI: 0.5%-98.8%; τ^2=5.4) (Table 1 & Figure 2). Prevalence estimates varied considerably by country and ranged from 99.2% in Somalia [58] to 0.3% in Uganda [54]. Out of

a total of 283,437 girls aged 0-14 years in 23 countries, 46,713 girls had FGM/C and this gave a

pooled prevalence of 7.3% (95% CI: 3.1-16.0%; PI: 0.1-88.9%; τ^2=4.8). The country level

prevalence ranged between 72.7% in Mali [46] and 0.1% in Ghana [41] (Table 1, Figure 3).

Amongst included countries, the total estimated prevalence was 86,080,915 women (95%CI:

46,736,701–133,693,929) and 11,982,031 girls with FGM/C (95% CI: 5,123,351–26,476,156)

(Table 1).

Within AFR, the prevalence amongst women was 32.0% (95% CI: 16.2-53.5%; PI: 0.5-97.8%;

τ^2=4.6) while amongst girls, it was 7.1% (95% CI: 2.7-17.8%; PI: 0.1-90.9%; τ^2=5.0). This

provides a regional estimate of 53,533,504 (95% CI: 28,096,309 – 89,406,470) women with

FGM/C and 9,193,035 (95% CI: 3,424,856 – 22,905,335) girls with FGM/C. Within EMR, the

prevalence amongst women was 73.7% (95% CI: 21.0-96.7%; PI: 0.02-1%; τ^2=7.2), while

amongst girls it was 12.0% (95% CI: 2.1-46.7%; PI: 0-99.9%; τ^2=3.6). This provides a EMR

regional estimate of 42,249,544 (95% CI: 12,041,808 – 56,034,547) women with FGM/C and

4,382,987 (95% CI: 762,100 – 17,014,158) girls with FGM/C.

Among available nationally representative surveys that ranged between 1994 and 2020, most

countries showed a decline in the prevalence of FGM/C across repeated cross-sections of women

(23 countries) and girls (25 countries) (Table 2). In addition, among repeated cross-sections of

women, 6 countries showed a minor decrease in prevalence (0-3%) and three countries showed

an increase in the prevalence of FGM/C. In particular, there was an increase from 97.9% to

99.2% in Somalia (2006 to 2020), an increase from 71.6 to 75.8% in (1998-99 to 2010), and an

increase from 44.5% to 52.1% in Guinea-Bissau (2006 to 2018-19). For repeated cross-sections

of girls, 7 countries had a minor decrease in prevalence (0-3%) and two countries had an increase

(Djibouti: 48.5% in 2006, to 58% in 2010; and Cameroon: 0.7% in 2004, to 1% in 2010). The

largest decline was in Central African Republic (43.4% in 1994-95, to 21.6% in 2018-19) among

repeated cross-sections of women; and in Ethiopia from 51.9% in 2000 to 15.7% in 2016, which

was among women who reported having at least one daughter who had FGM/C.

Twenty-three of the 28 national reports recorded FGM/C type for women (Table 3). In MICS

and DHS Type I and II were described as "cut with flesh removed", Type III was described as

"sewn closed" and Type IV was described as "nicked" or "cut". Amongst women, the type "flesh

removed" was the most common type in 19 countries, "nicked" was the least common type in 13

countries and "sewn closed" was most common amongst women in two countries (Sudan (77%)
and Central African Republic (49.6%)). The pooled proportion of women with FGM/C that were
"nicked" was 4.8% (95% CI: 2.9-8.1%) (Figure 4a), had "flesh removed" was 65.7% (95% CI:
56.7-73.8%) (Figure 4b), or had their genital area "sewn closed" was 12.1% (CI: 7.4% -19.4%)
(Figure 4c). No pooled proportion of types was conducted amongst girls due to inconsistent
reporting of types and because the type of FMG/C was only collected in 14 out of 23 countries.
Amongst girls with FGM/C, "not sewn closed" and "flesh removed" were the most common type
in 6 countries each and "sewn closed" was the least common type in 7 countries although it was
the most common type in Sierra Leone (83.3%). Surveys using the terms "not sewn closed" may
refer to Types, I, II, and IV (Table 3).

In all countries, for the majority of women and girls, FGM/C was performed by traditional
circumcisers, whilst a lower proportion was performed by medical professionals. The exception
was girls in Egypt, where the proportion of FGM/C performed by medical professionals was
81.9% (Table 4) [55]. For women, in all countries where age of FGM/C was reported, FGM/C
was most commonly performed at early ages (0-5 years) except for Kenya, Egypt, Sierra Leone,
Guinea, and Tanzania where the procedure was most commonly done at 9-14 years, and Somalia
where it was most commonly done at 5-9 years. For girls, the highest proportion of FGM/C was
performed at the lowest age category: under 1 year of age (seven countries). Exceptions include
Burkina Faso, Gambia, and Tanzania where the category 1-4 years had higher proportions, Sierra
Leone, Kenya, and Guinea (most commonly done at 5-9 years), Egypt (most commonly done at
11-12 years) and Somalia (10-14 years).

Sub-regional studies

Thirty-three sub-regional studies were from 13 countries, with ten from EMR and 23 from AFR.
Among studies including women, the highest FGM/C prevalence was in Somaliland, Somalia
(99.1%) [60] and the lowest was in Axum Town, North Ethiopia (0.7%) [61]. Regarding the 17
sub-regional studies including girls, the highest FGM/C prevalence was in Kersa, Ethiopia
(88.1%) [62] and the lowest was in Axum Town, Ethiopia (0%) [61] (S5 Results, S6 Table).
Eight out of the 33 sub-regional studies reported on FGM/C type. Type IV was most common in
one study [63] , Type II was the most common in four studies [64-67] and "sewn closed" was the

most common in two sub-regional DHS reports on Somaliland [60] and the Northeast Zone of

Somalia [68] (S5 Results: S7 Table). In 12 studies, the most common performers of FGM/C

were traditional circumcisers [62, 63, 66, 69-77]. In three studies, in Egypt [78, 79] and Saudi

Arabia [80] medical professionals were more common (S5 Results: S8 Table).

School, Community or Facility based studies excluding studies on migrant populations

Within 98 non population-based studies, 54 studies (excluding studies on migrant populations)

were from 15 countries, with 30 studies from countries in AFR, three studies from Malaysia in

SEAR, and 21 studies from countries in EMR (S6 Results: S9 Table). Thirty-one were

hospital/clinic-based, 14 school-based, and nine community-based studies. School and

university-based studies reported a prevalence ranging from 9.4% [81] to 83.3% [82]; hospital or

clinic-based studies reported a prevalence from 13% [83] to 100% [84], and community-based

studies reported a prevalence from 0.4% [85] to 99.3% [86] (S6 Results: S10 Table). Two had

prospective designs, two were retrospective, one was a cohort study, and 49 were cross-sectional.

Twenty-five studies reported on FGM/C types. In ten studies Type I was most common [83, 87-

95], Type II was most common in four studies [96-99], Type III in three studies [100-102], and

Type IV in two studies [86, 103] (S6 Results: S11 Table).

Studies on migrant populations

Within the 98 non-population-based studies, 44 studies on migrant populations with FGM/C

were identified. The included studies were from the Region of the Americas (AMR) (9 studies),

European Region (EUR) (25 studies), Western Pacific Region (WPR) (5 studies), and EMR (5

studies) (S7 Results: S13 Table). Most studies had a moderate risk of bias and four had a high

risk of bias. Participants in these studies were categorized as migrants, refugees, or asylum

seekers. Studies design were case control (n=1), and randomised controlled trial (n=1),

population based (n=5), retrospective or database studies (n=5), and cross-sectional studies

(n=15), case series (n=17). Prevalence within these migrant populations ranged from 0.32% (of a

sample of 145,492) [104] to 99% (of a sample of 191) [105] (S8 Results: S14 Table). Type II

[106-114] and Type III [104, 105, 115-120] were most common in 9 studies each, followed by

Type I (8 studies) [121-128], and Type IV (three studies) [129-131] (S7 Results: S15 Table).

Discussion

This systematic review and meta-analysis estimated that nearly 100 million girls and women of reproductive age had FGM/C, which was among countries included in the analysis. Results indicated that the practice remains widespread in countries where it is reported. In particular, across 28 countries there was a prevalence of 38% among women aged 15-49 years old, and across 23 countries, there was a pooled prevalence of 7% among girls aged 0-14 years old. Over repeated cross-sectional surveys, the prevalence of FGM/C appears to have decreased in 23 countries for women and 25 countries for girls. It appears to have increased in three countries for women (Guinea-Bissau, Burkina Faso, and Somalia) and two countries for girls (Djibouti and Cameroon). For both women and girls who had FGM, most had the type "flesh removed" (Types I and II) and "sewn closed" (Type III), the most severe type of FMG/C, was practised over three-quarters of women and girls in Sudan and Sierra Leone. In most countries, FGM/C commonly occurred in early childhood and was performed by traditional circumcisers. FGM/C appears to continue in those who migrate from countries where FGM/C is prevalent.

The total prevalence of FGM/C specified in this study is consistent with previous estimates of FGM/C among girls and women of reproductive age where estimates of FGM/C range from 100-140 million women and girls [2, 3]. Our study findings differ to the most recent UNICEF report, which states the global prevalence of FGM/C to be over 200 million among living women and girls; although the upper end of the combined confidence interval was close to this estimate [1, 4]. UNICEF extrapolated their prevalence to women of all ages and this study was unable to locate reports to provide an estimate for women from Djibouti, women and girls from Indonesia and this study excluded estimates from surveys that used a household level prevalence of FGM/C among girls.

The decline of FGM/C across repeated cross-sectional studies in many countries is encouraging and corresponds with previous research, which showed an absolute decline in the prevalence of FGM/C amongst girls aged 0-14 years by 51.8%; from 67.6% in 1990-1996 to 15.8% in 2015-2017 [21]. Results were consistent with previous research regarding large variations in prevalence between countries and regions [5, 21, 132].

Structural level changes including legislative bans and policy changes are likely to play a role in the possible decline. Globally, there are 84 countries that either have specific legislation that

bans FGM/C or other legislation that enables the persecution of FGM/C [133, 134]. In Egypt, the

lower prevalence for girls may relate to the legal ban implemented in 2008 [55]. However, the

efficacy of laws against FGM/C depend on enforcement and the specificities of the law. For

example, in Liberia and Mauritania laws only protect girls below the age of 18 [134, 135] and in

Indonesia, FGM/C was legalized in a medical setting in 2010, however, the repeal of that law in

2014 left no explicit ban or consequences [134, 136]. In Somalia, there is no national legislation

that enforces the Somalia constitution which states that "circumcision is prohibited" [133, 134].

Furthermore, there is no legislative ban in Mali and the prevalence remains high at 88.6% of

women and 72.7% of girls [46].

In addition to legislation and judicial enforcement, other mechanisms may have contributed to a

reduction in FGM/C, such as education, literacy and change in social norms [137, 138]. To end

the propagation of FGM/C future research should undertake process evaluations of structural,

community and family level interventions and policies in countries where FGM/C has declined.

Understanding the underlying mechanisms for change in FGM/C, in countries where there has

been success, will be instrumental for the adoption of effective policies and interventions to meet

the SDG target 5.3.

Consistent with other studies, the most common FGM/C type amongst women and girls was 'cut

with flesh removed', equivalent to Type I or II [5, 139]. Koski and colleagues reported that there

were no significant differences regarding the types and severity of FGM/C across cohorts [5].

Similar to other findings, this review found that FGM/C most often occurs in early childhood

[139].

Similar to the findings of this study, UNICEF reported that traditional circumcisers perform most

procedures. Yet, the opposite occurs in Egypt where medicalization of FGM/C was high despite

its ban [55]. WHO and UNICEF have called for the end of medicalization of FGM/C [140, 141].

Discussions around the medicalisation of FGM/C are beyond the scope of this study but this has

been discussed elsewhere [140, 142, 143].

Studies of different regions or facilities in the same countries had different prevalence reports, a

phenomenon also reported by UNICEF [139], likely owing to regional or community risk

factors. For example, the national prevalence in Ethiopian women was 65.2% [39], while in one

region, the East Gojjam Zone, it was 96% [72]. Studies based on migrant populations have

widely varying prevalence estimates. They demonstrate that FGM/C is present in countries

where it is not traditionally practiced; however, high quality studies are needed to understand

FGM/C in these countries, and to inform policies, interventions, and relevant healthcare services.

The strengths of the study ensure a thorough and accurate examination of the research question.

The review had broad inclusion criteria to provide a comprehensive review of all FGM/C

studies. The study used robust methods to identify studies, extract data, and present findings. The

broadest possible scope of research was scanned with no restrictions on language. A hand search

of grey literature was conducted to be as comprehensive as possible. Moreover, DHS and MICS

data, which are collected via representative sampling methodology with high response rates and

a low risk of bias, ensured the quality of the meta-analyses.

This study had several limitations. There were two missing country reports unavailable for

analysis (S1 Methods and Results, S1 Text). The actual global total number of girls and women

with FGM/C will be higher than that reported in this study due to missing data from key

countries. For example, Indonesia was not included in the meta-analysis due lack of a

denominator. FGM/C was self-reported, thus the prevalence estimates may be underreported due

to legal ramifications or social desirability. Furthermore, the translation of terms within surveys

may impact recall and comprehension, which emphasizes the need for survey tools to be

validated within each context. In addition, women and girls may not be able to accurately recall

the type of procedure performed on them, or there may be confusion due to multiple ways of

describing each type [144]. Furthermore, recollection of who performed the procedure may be

inaccurate [145].

The prevalence in the 0-14 age group may be underreported as these girls are still at risk of

FGM/C at the time of survey. Future research should adjust prevalence by age at FGM/C

procedure or conduct analyses based on age cohorts to be inclusive of those still at risk of

FGM/C. A future study examining FGM/C prevalence among five-year age cohorts will be

useful to understand if trends exist across age groups [139]. This study also shows the need for

consistency in future research regarding the denominator of FGM/C among girls and

terminology used to describe each type of FGM/C.

This study highlights the need to expand data collection and surveillance using robust

methodologies particularly in high resource countries with migrant populations from countries

that practice FGM/C. There are numerous data gaps on the national prevalence of FGM/C in

multiple countries, including: Colombia, Georgia, Russia, Iran, Oman, Kuwait, Singapore,

Thailand, the Philippines, India, Pakistan, Ecuador, Peru, Saudi Arabia, the State of Palestine, Sri

Lanka and United Arab Emirates [146]. In Indonesia approximately 50% of girls aged 0-14 had

FGM/C; however, we know relatively little about FGM/C in Indonesia, which warrants further

investigation given its large population size.

In conclusion, approximately 100 million women and girls have had FGM/C among countries

included in the analysis, and there is large variation between countries in progress to ending

FGM/C by 2030. Current findings may be used as a baseline in future attempts to track progress

to meeting SDG 5.3. A decline to end FGM/C across future generation of girls may be possible

in the near future in low-prevalence countries such as Niger, Uganda, and Ghana. However, the

decline in FGM/C must be greater in countries where the current prevalence of FGM/C is higher

such as Egypt, Sudan, Indonesia, Somalia, Djibouti, Guinea, and Mali, which emphasizes the

need for immediate interventions and policies to end this harmful practice.

Declaration of interests

We declare no competing interests.

Data sharing statement

All data generated or analysed for this study are included in this article and its supplementary

files.

Contributors

SM conceived the study and SA, C Akl, and C Akik contributed to the study design. LF and SM

wrote the protocol with contributions from SA, C Akl, C Akik. LF completed the literature

search. LF and ZD selected the studies and extracted relevant data. LF analysed the data and

wrote the first draft of the paper. SM, C Akl, C Akik, SA, and ZD revised drafts and approved

the final manuscript. SM supervised LF, and SM is the guarantor of the study.

Acknowledgements

We thank Dr Marie-Claire Rebeiz, Mrs Tanya Khoury, and Ms Sara Mansour who verified the

data in the table.

Supporting information

Captions for Figures:

Figure 2. Footnote: There were 30 studies included in the systematic review as nationally-
representative studies, however, The Pew Research Study [31] only did not include women and
the Indonesia RISKESDAS [30] did not report sample sizes, thus they were not included in this
analysis.

Figure 3. Footnote: There were 30 studies included in the systematic review as nationally-
representative studies, however, surveys from surveys from Liberia [45], Niger [49], and Uganda
[54] did not include girls, and The Pew Research Study [31], Yemen [33], and Eritrea [32]only
included women who report on at least one daughter in their household who has had FGM/C and
the Indonesia RISKESDAS [30] did not report sample sizes, thus they were not included in this
analysis.

S1 Methods and Results

S1 Table. Search Strategy

S2 Table. Inter-rater reliability rate at different stages of the screening process.

Footnote: A third reviewer confirmed the inclusion of all studies. The Cohen's kappa provided a
global score across all three inclusion criteria; after the full text screening it was decided that the
risk factors of FGM/C would be presented in separate paper. At stage 1, reviewers had the option
to indicate if they were unsure, which may also partially explain the low score before resolution.
Agreement was higher on the first two points of the inclusion criteria: (i) prevalence studies and
(ii) non-population based studies examining FGM/C.

S1 Text. Inclusion and Exclusion Criteria.

S3 Table. Quality assessment checklist for prevalence studies.

Footnote: Adapted from Hoy and Colleagues [20].

S2 Text. Supplementary results.

S2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

Checklist

S3 Study Protocol

S1 Fig. Funnel plot of FGM/C prevalence in Women of Reproductive Age (15-49 years old) in

Nationally Representative Studies.

S2 Fig. Funnel plot of FGM/C prevalence in Girls (0-14 years old) in Nationally Representative

Studies.

S4 Results: Nationally representative studies

S4 Table. Characteristics of nationally representative studies.

Footnote: Abbreviations: AFR: African Region; DHS: Demographic and Health Survey; EMR:
Eastern Mediterranean Region; MICS: Multiple Indicator ClusterSurveys; SEAR: South-
EastAsia Region; WHO: World Health Organization.
520
521 Legend*Not included in meta-analysis.
522

S5 Results: Sub-Regional Population-Based Studies

S5 Table. Characteristics of Sub-Regional Population-Based Studies.

Legend: *Patient report and examination, all others: Patient Report † women reported that at
least 1 daughter had FGM/C in the household.

Footnote: All studies used cross-sectional methods.

S6 Table. Prevalence of FGM/C in Women and Girls in Sub-Regional Population-Based Studies.

Footnote: Abbreviations: AFR: African Region EMR: Eastern Mediterranean Region, FGM/C:

Female Genital Mutilation/Cutting

Legend: * Women reported that at least 1 daughter had FGM/C in the household.. † Youngest
daughter had FGM/C. ‡ Due to inconsistent data reported in the study, this number was
calculated by the authors of this review.

S7 Table. Types of FGM/C in Sub-Regional Population-Based Studies.

Legend * % of Women † % of youngest daughter ‡ % of girls

Footnote: Somaliland and Northeast Zone MICS calculate the preavelnce of type out of the total
number of participants, and report type 2 as "flesh removed" and type 3 as "sewn closed".
Abberviations FGM/C: Female Genital Mutilation/Cutting

S8 Table. Characteristics of FGM/C Procedure in Sub-Regional Population-Based Studies.

Footnote Abbreviations: AFR: African Region EMR: Eastern Mediterranean Region Female
Genital Mutilation/Cutting

S6 Results: School, Community or Facility based studies excluding studies on migrant
populations

S9 Table. Characteristics of School, Community or Facility based studies excluding studies on
migrant populations.

Legend: *****Types of FGM/C mentioned were: Clitoral tip excision, Complete clitoridectomy,
Clitoridectomy/labia minora Excision, Clitoridectomy/labia minora/Inner majora excision.

Footnote: Abbreviations: AFR: African Region EMR: Eastern Mediterranean Region SEAR:
South East Asian Region

S10 Table. Proportion of FGM/C in Women and Girls in School, Community or Facility based
studies excluding studies on migrant populations.

Legend: *Out of the female school teachers **Without excluding those who were unsure if they
had been mutilated.*** Prevalence according to clinical examination.

Footnote: Abbreviations: AFR: African Region EMR: Eastern Mediterranean Region, SEAR:
South East Asian Region, FGM/C: Female Genital Mutilation/Cutting

S11 Table. Types of FGM/C in School, Community or Facility based studies excluding studies
on migrant populations.

Footnote: Abbreviations: AFR: African Region EMR: Eastern Mediterranean Region SEAR:
South East Asian Region, FGM/C: Female Genital Mutilation/Cutting

S12 Table. Characteristics of FGM/C Procedure in School, Community or Facility based studies
excluding studies on migrant populations. Female Genital Mutilation/Cutting

Footnote: Abbreviations: AFR: African Region EMR: Eastern Mediterranean Region SEAR:
South East Asian Region FGM/C: Female Genital Mutilation/Cutting

S7 Results: Studies on Migrant Populations.

S13 Table. Characteristics of Studies on Migrant Populations.

Legend: * Tissue removed and sewn closed, tissue removed and some stitching, some tissue
removed, pricking. † Flesh removed, Genital area just nicked, Genital area sewn closed

Footnote: Abbreviations: EMR: Eastern Mediterranean Region. SEAR: South East Asian
Region. EUR: European Region. WPR: Western Pacific Region AMR: American Region

S14 Table. Prevalence of FGM/C in Migrant Populations.

Footnote: Abbreviations: EMR: Eastern Mediterranean Region. SEAR: South East Asian
Region. EUR: European Region. WPR: Western Pacific Region AMR: American Region
FGM/C: Female Genital Mutilation/Cutting

S15 Table. Types of FGM/C in Migrant Populations.

Legend: *Flesh removed and some stitching † Flesh removed and sown closed.
Footnote: Abbreviations: EMR: Eastern Mediterranean Region. SEAR: South East Asian
Region. EUR: European Region. WPR: Western Pacific Region AMR: American Region
FGM/C: Female Genital Mutilation/Cutting

S16 Table. Characteristics of FGM/C Procedure for Migrant Populations.

Footnote: Abbreviations: EMR: Eastern Mediterranean Region. SEAR: South East Asian
Region. EUR: European Region. WPR: Western Pacific Region AMR: American Region
FGM/C: Female Genital Mutilation/Cutting

References

1.	UNICEF. Female Genital Mutilation: UNICEF; 2022. Available from: https://data.unicef.org/topic/child-protection/female-genital-mutilation/ Date Accessed: 22-04-2022.
2.	UNFPA. Demographic Perspectives on Female Genital Mutilation New York: UNFPA; 2015. Available from: https://sustainabledevelopment.un.org/content/documents/19961027123_UN_Demograhics_v3%20(1).pdf Date Accessed: 22-04-2022.
3.	Population Reference Bureau. Female Genital Mutilation/Cutting: Data and Trends Update 2014 – Infographic 2014. Available from: https://www.prb.org/resources/female-genital-mutilation-cutting-data-and-trends-update-2014/ Date Accessed: 22-04-2022.
4.	UNICEF. Female Genital Mutilation/Cutting: A global concern New York: UNICEF; 2016. Available from: https://www.unicef.org/media/files/FGMC_2016_brochure_final_UNICEF_SPREAD.pdf Date Accessed: 22-04-2022.
5.	Koski A, Heymann J. Thirty-year trends in the prevalence and severity of female genital mutilation: a comparison of 22 countries. BMJ Global Health. 2017;2(4):e000467. PubMed PMID: 29225952.
6.	Kandala NB, Ezejimofor MC, Uthman OA, Komba P. Secular trends in the prevalence of female genital mutilation/cutting among girls: a systematic analysis. Bmj Global Health. 2018;3(5). doi: 10.1136/bmjgh-2017-000549. PubMed PMID: WOS:000457716300001.
7.	El-Dirani Z, Farouki L, Akl C, Ali U, Akik C, McCall SJ. Factors associated with female genital mutilation: a systematic review and synthesis of national, regional and community-based studies. BMJ Sexual & Reproductive Health. 2022:bmjsrh-2021-201399. doi: 10.1136/bmjsrh-2021-201399.
8.	Kobach A, Ruf-Leuschner M, Elbert T. Psychopathological sequelae of female genital mutilation and their neuroendocrinological associations. BMC Psychiatry. 2018;18(1):187. PubMed PMID: 29895282.
9.	Reisel D, Creighton SM. Long term health consequences of Female Genital Mutilation (FGM). Maturitas. 2015;80(1):48-51. PubMed PMID: 25466303.
10.	Sarayloo K. RR, Elhadi A. Health consequences of the female genital mutilation: a systematic review. Galen Medical Journal 2018;8:1336. 2019.
11.	Lurie JM, Weidman A, Huynh S, Delgado D, Easthausen I, Kaur G. Painful gynecologic and obstetric complications of female genital mutilation/cutting: A systematic review and meta-analysis. PLoS medicine. 2020;17(3):e1003088-e. doi: 10.1371/journal.pmed.1003088.
12.	Tordrup D, Bishop C, Green N, Petzold M, Vallejo FR, Vogel JP, et al. Economic burden of female genital mutilation in 27 high-prevalence countries. BMJ global health. 2022;7(2). doi: 10.1136/bmjgh-2020-004512.
13.	Odukogbe ATA, Afolabi BB, Bello OO, Adeyanju AS. Female genital mutilation/cutting in Africa. Translational Andrology and Urology. 2017;6(2):138-48. doi: 10.21037/tau.2016.12.01.
14.	World Health Organisation. Female genital mutilation 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/female-genital-mutilation Date Accessed: 02-05-2022.
15.	Banks E, Meirik O, Farley T, Akande O, Bathija H, Ali M. Female genital mutilation and obstetric outcome: WHO collaborative prospective study in six African countries. Lancet. 2006;367(9525):1835-41. doi: 10.1016/s0140-6736(06)68805-3. PubMed PMID: 16753486.
16.	Evidence Partners. DistillerSR. Version 2.35. . Available from: https://www.evidencepartners.com. Accessed: March 2020-April 2022.
17.	Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint—Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Physical therapy. 2009;89(9):873-80. doi: 10.1093/ptj/89.9.873.

18.   Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Online). 2021;372. doi: 10.1136/bmj.n71.

19.   Farouki L, Abdulrahim, S., Akl, C., Akik, C., McCall, S. The global prevalence, distribution and determinants of female genital mutilation: a protocol for a systematic review and meta-analysis. Open Science Framework. 2020.

20.   Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. Journal of clinical epidemiology. 2012;65(9):934-9. doi: 10.1016/j.jclinepi.2011.11.014.

21.   Kandala NB, Ezejimofor MC, Uthman OA, Komba P. Secular trends in the prevalence of female genital mutilation/cutting among girls: a systematic analysis. BMJ Global Health. 2018;3(5):e000549. PubMed PMID: 30483404.

22.   Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557. doi: 10.1136/bmj.327.7414.557.

23.   Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, et al. Meta-analysis of prevalence: I 2 statistic and how to deal with heterogeneity. Research synthesis methods. 2022.

24.   Spineli LM, Pandis N. Prediction interval in random-effects meta-analysis. American journal of orthodontics and dentofacial orthopedics. 2020;157(4):586-8. doi: 10.1016/j.ajodo.2019.12.011.

25.   Higgins JPT. Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. International Journal of Epidemiology. 2008;37(5):1158-60. doi: 10.1093/ije/dyn204.

26.   Lin L, Chu H. Meta-analysis of Proportions Using Generalized Linear Mixed Models. Epidemiology (Cambridge, Mass). 2020;31(5):713-7. doi: 10.1097/EDE.0000000000001232.

27.   Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Archives of Public Health. 2014;72(1):39. doi: 10.1186/2049-3258-72-39.

28.   Kumar M. Funnel Plots for Proportion Data 2018. Available from: https://cran.r-project.org/web/packages/funnelR/index.html Date Accessed: 23-04-22.

29.   UN Department of Economic and Social Affairs Population Dynamics. Quinquennial Population by Five-Year Age Groups - Female. 2019.

30.   Health Research and Development Agency. Riset Kesehatan Dasar (RISKESDAS) 2013. Indonesia: Government of Indonesia, 2013.

31.   Pew Research Center. Tolerance and Tension: Islam and Christianity in Sub-Saharan Africa. Pew Research Center, 2010.

32.   National Statistics Office Fafo Institute For Applied International Studies. Eritrea Population and Health Survey 2010. Asmara, Eritrea: World Health Organisation, 2013.

33.   Ministry of Public Health and Population. Yemen National Health and Demographic Survey 2013. Rockville, Maryland, USA: MOPHP, CSO, PAPFAM, and ICF International, 2015.

34.   Institut national de la statistique et de l'analyse économique (INSAE). Enquête par grappes à indicateurs multiples 2014, Rapport final. Cotonou, Bénin: UNICEF, 2015.

35.   Institut National de la Statistique et de la DÈmographie IBF, International ICF. Burkina Faso EnquÍte DÈmographique et de SantÈ et ‡ Indicateurs Multiples (EDSBF-MICS IV) 2010. Calverton, Maryland, USA: Institut National de la Statistique et de la DÈmographie - INSD/Burkina Faso and ICF International, 2012.

36.   Institut Centrafricain des Statistiques et des Etudes Economiques et Sociales. Central African Republic Multiple Indicator Cluster Survey 2018-2019 Bangui, République Centrafricaine: UNICEF, 2021.

37.   INSEED and UNICEF. Enquête par grappes à indicateurs multiples Tchad 2019. N'Djamena, Tchad: UNICEF, 2021.

38.   Institute National de la Statistique. Enquête par grappes à indicateurs multiples - Côte d'Ivoire 2016. Cote D'Ivoire: UNICEF, 2017.

39.   Central Statistical Agency & ICF. Ethiopia Demographic and Health Survey 2016. Addis Ababa, Ethiopia: CSA and ICF, 2017.

40.   Gambia Bureau of Statistics. The Gambia Demographic and Health Survey 2019-20. Banjul, The Gambia: The DHS Program ICF Rockville, Maryland, USA, 2021.
41.   Ghana Statistical Service. Multiple Indicator Cluster Survey (MICS2017/18), Survey Findings Report. Accra, Ghana: UNICEF, 2018.
42.   Institut National de la Statistique Ministère du Plan et du Développement Economique & ICF. République de Guinée Enquête Démographique et de Santé 2018. Conakry, Guinée: The DHS Program, ICF Rockville, Maryland, USA, 2019.
43.   Ministério da Economia e Finanças D-GdP, Instituto Nacional de Estatistica,. Inquérito aos Indicadores Múltiplos (MICS6) 2018-2019, Relatório Final. Bissau, Guiné-Bissau: UNICEF, 2020.
44.   Kenya National Bureau of Statistics & ICF. Kenya Demographic and Health Survey 2014. Rockville, MD, USA: Kenya National Bureau of Statistics and ICF International, 2015.
45.   Liberia Institute of Statistics and Geo-Information Services. Liberia Demographic and Health Survey 2019-20 - Key Indicators Report. Monrovia, Liberia: LSGIS ICF International, 2020.
46.   Institut National de la Statistique (INSTAT) Cellule de Planification et de Statistique Secteur Santé-Développement Social et Promotion de la Famille (CPS/SS-DS-PF) & ICF. Mali Demographic and Health Survey 2018. Bamako, Mali: INSTAT/CPS/SS-DS-PF and ICF, 2019.
47.   Mauritania National Statistics Office. Enquête par Grappes à Indicateurs Multiples, 2015, Résultats clés. Nouakchott, Mauritanie: UNICEF, 2016.
48.   National Population Commission (NPC) [Nigeria] & ICF. Nigeria Demographic and Health Survey 2018 - Final Report. Abuja, Nigeria: NPC and ICF, 2019.
49.   Institut National de la Statistique INSN, International ICF. Niger Enquéte Demographique et de Santè et ‡ Indicateurs Multiples (EDSN-MICS IV) 2012. Calverton, Maryland, USA: INS/Niger and ICF International, 2013.
50.   Agence Nationale de la Statistique et de la Démographie (ANSD). Enquête Démographique et de Santé Continue - EDS-Continue 2019. Dakar, Sénégal: The DHS Program ICF Rockville, Maryland, USA 2020.
51.   Statistics Sierra Leone & ICF. Sierra Leone Demographic and Health Survey 2019. Freetown, Sierra Leone: Ministry of Health and Sanitation and ICF International, 2020.
52.   Ministry of Health Tanzania and Zanzibar National Bureau of Statistics Office of Chief Government Statistician Zanzibar ICF. Tanzania Demographic and Health Survey and Malaria Indicator Survey 2015-2016. Dar es Salaam, Tanzania: MoHCDGEC, MoH, NBS, OCGS, and ICF, 2016.
53.   Institut National de la Statistique et des Etudes Economiques et Démographiques. Togo - Enquête à Indicateurs Multiples 2017, Rapport final. Lomé, Togo: UNICEF, 2018.
54.   Uganda Bureau of Statistics and ICF. Uganda Demographic and Health Survey 2016. Kampala, Uganda: UBOS and ICF, 2018.
55.   Ministry of Health Population El Zanaty and associates and ICF International. Egypt Demographic and Health Survey 2014. Cairo, Egypt: Ministry of Health and Population and ICF International, 2015.
56.   Central Statistical Organization. Iraq Multiple Indicator Cluster Survey 2018 Survey Findings Report. Iraq: UNICEF, 2019.
57.   Central Bureau of Statistics & UNICEF Sudan. Multiple Indicator Cluster Survey 2014 of Sudan, Final Report. Khartoum, Sudan: UNICEF, 2016.
58.   Directorate of National Statistics. Somalia Health and Demographic Survey 2020. Federal Government of Somalia, United Nations Population Fund, 2020.
59.   Ministry of Health and ICF. Maldives Demographic and Health Survey 2016-17. Malé, Maldives: MOH and ICF, 2018.
60.   Phadungkiatwattana P, Rujivejpongsathron J, Tunsatit T, Yanase Y. Analyzing pregnancy outcomes in women of extremely advanced maternal age (> or = 45 years). J Med Assoc Thai. 2014;97(1):1-6. PubMed PMID: 24701722.

61.   Gebrekirstos K, Abebe M, Fantahun A. A cross sectional study on factors associated with harmful traditional practices among children less than 5 years in Axum town, north Ethiopia, 2013. Reproductive Health. 2014;11:46. PubMed PMID: 24952584.

62.   Yirga WS, Kassa NA, Gebremichael MW, Aro AR. Female genital mutilation: prevalence, perceptions and effect on women's health in Kersa district of Ethiopia. International Journal of Women's Health. 2012;4:45-54. PubMed PMID: 22371659.

63.   Gudeta TA, Regassa TM, Gamtessa LC. Female genital mutilation: prevalence, associated factors and health consequences among reproductive age group women in Keffa Zone, Southwest, Ethiopia. Reproductive Health. 2022;19(1):9. doi: 10.1186/s12978-022-01364-3. PubMed PMID: WOS:000764993700001.

64.   Bogale D, Markos D, Kaso M. Prevalence of female genital mutilation and its effect on women's health in Bale zone, Ethiopia: a cross-sectional study. BMC public health. 2014;14:1076. doi: 10.1186/1471-2458-14-1076.

65.   Johnson OE, Okon RD. Perception and practice of female genital cutting in a rural community in southern Nigeria. African journal of reproductive health. 2012;16(4):132-9.

66.   Greis A, Barnighausen T, Bountogo M, Ouermi L, Sie A, Harling G. Attitudes towards female genital cutting among adolescents in rural Burkina Faso: a multilevel analysis. Tropical Medicine & International Health. 2020;25(1):119-31. PubMed PMID: 31698528.

67.   Greis A, Barnighausen T, Bountogo M, Ouermi L, Si A, Harling G. Attitudes towards female genital cutting among adolescents in rural Burkina Faso: a multilevel analysis. Tropical Medicine & International Health. 2020;25(1):119-31. doi: 10.1111/tmi.13338. PubMed PMID: WOS:000509501600013.

68.   Northeast Somalia Ministry of Planning and International Cooperation. Northeast Zone, Somalia Monitoring the situation of children and women Multiple Indicator Cluster Survey 2011 Nairobi, Kenya: UNICEF, 2014.

69.   Oljira T, Assefa N, Dessie Y. Female genital mutilation among mothers and daughters in Harar, eastern Ethiopia. International Journal of Gynaecology & Obstetrics. 2016;135(3):304-9. PubMed PMID: 27609740.

70.   Gajaa M, Wakgari N, Kebede Y, Derseh L. Prevalence and associated factors of circumcision among daughters of reproductive aged women in the Hababo Guduru District, Western Ethiopia: a cross-sectional study. BMC Women's Health. 2016;16:42. PubMed PMID: 27449648.

71.   Mitike G, Deressa W. Prevalence and associated factors of female genital mutilation among Somali refugees in eastern Ethiopia: a cross-sectional study. BMC Public Health. 2009;9:264. PubMed PMID: 19635149.

72.   Andualem M. Determinants of Female Genital Mutilation Practices in East Gojjam Zone, Western Amhara, Ethiopia. Ethiopian Medical Journal. 2016;54(3):109-16. PubMed PMID: 29115777.

73.   Abebe S, Dessalegn M, Hailu Y, Makonnen M. Prevalence and Barriers to Ending Female Genital Cutting: The Case of Afar and Amhara Regions of Ethiopia. International Journal of Environmental Research and Public Health. 2020;17(21):16. doi: 10.3390/ijerph17217960. PubMed PMID: WOS:000588904300001.

74.   Ifeanyichukwu OA, Oluwaseyi A, Adetunji L. Female genital mutilation: Attitude and practices among women in Okada community, Edo state. Journal of Medicine and Biomedical Research. 2015;14(2):138-50.

75.   Johnson OE, Okon RD. Perception and practice of female genital cutting in a rural community in southern Nigeria. African Journal of Reproductive Health. 2012;16(4):132-9. PubMed PMID: 23444550.

76.   Bjalkander O, Leigh B, Harman G, Bergstrom S, Almroth L. Female genital mutilation in Sierra Leone: who are the decision makers? African Journal of Reproductive Health. 2012;16(4):119-31. PubMed PMID: 23444549.

77.   Mohammed ES, Seedhom AE, Mahfouz EM. Female genital mutilation: current awareness, believes and future intention in rural Egypt. Reproductive Health. 2018;15(1):175. PubMed PMID: 30333019.

78.   Salama I, Sami S, Rabah T, Salama S, Mohsin AA. Female genital mutilation among egyptian school children. European Journal of Pediatrics. 2017;176(11):1463-4. doi: 10.1007/s00431-017-2979-8.
79.   Zayed AA, Ali AA. Abusing female children by circumcision is continued in Egypt. Journal of Forensic & Legal Medicine. 2012;19(4):196-200. PubMed PMID: 22520370.
80.   Milaat WA, Ibrahim NK, Albar HM. Reproductive health profile and circumcision of females in the Hali semi-urban region, Saudi Arabia: A community-based crosssectional survey. Annals of Saudi Medicine. 2018;38(2):81-9. doi: 10.5144/0256-4947.2018.81.
81.   Chinawa AT, Chinawa JM, Ossai EN, Aronu AE, Ozokoli GE, Enebe J. Pattern of Female Genital Mutilation among Adolescents Attending Secondary Schools' in Enugu Metropolis. Journal of Tropical Pediatrics. 2021;67(1):10. doi: 10.1093/tropej/fmaa103. PubMed PMID: WOS:000637542600031.
82.   Ali AA, Okud A, Mohammed AA, Abdelhadi MA. Prevalence of and factors affecting female genital mutilation among schoolgirls in Eastern Sudan. International Journal of Gynaecology & Obstetrics. 2013;120(3):288-9. PubMed PMID: 23219094.
83.   Garba ID, Muhammed Z, Abubakar IS, Yakasai IA. Prevalence of female genital mutilation among female infants in Kano, Northern Nigeria. Archives of Gynecology & Obstetrics. 2012;286(2):423-8. PubMed PMID: 22491808.
84.   Bjälkander O, Bangura L, Leigh B, Berggren V, Bergström S, Almroth L. Health complications of female genital mutilation in Sierra Leone. International Journal of Women's Health. 2012;4(1):321-31. doi: 10.2147/ijwh.s32670.
85.   Jimoh AO, Adaji SE, Adelaiye H, Olorukooba AA, Bawa U, Ibrahim HI, et al. A cross-sectional study of traditional practices affecting maternal and newborn health in rural Nigeria. The Pan African medical journal. 2018;31:64. PubMed PMID: 31007811.
86.   Rashid A, Iguchi Y. Female genital cutting in Malaysia: a mixed-methods study. BMJ Open. 2019;9(4):e025078. PubMed PMID: 30940756.
87.   Suleiman IR, Maro E, Shayo BC, Alloyce JP, Masenga G, Mahande MJ, et al. Trend in female genital mutilation and its associated adverse birth outcomes: A 10-year retrospective birth registry study in Northern Tanzania. Plos One. 2021;16(1):13. doi: 10.1371/journal.pone.0244888. PubMed PMID: WOS:000607915500017.
88.   Kaplan A, Forbes M, Bonhoure I, Utzet M, Martin M, Manneh M, et al. Female genital mutilation/cutting in The Gambia: long-term health consequences and complications during delivery and for the newborn. International Journal of Women's Health. 2013;5:323-31. PubMed PMID: 23843705.
89.   Gebremariam K, Assefa D, Weldegebreal F. Prevalence and associated factors of female genital cutting among young adult females in Jigjiga district, eastern Ethiopia: a cross-sectional mixed study. International Journal of Women's Health. 2016;8:357-65. PubMed PMID: 27563257.
90.   Mitwaly A AB, Abd El Aal DEM, Aziz PA, Hassanin AI, Abbas AM. A recent look for the implication and attitude of practicing female genital mutilation in upper Egypt: a cross sectional study. International Journal of Reproduction, Contraception, Obstetrics and Gynecology; Vol 6, No 10 (2017): October 2017DO - 1018203/2320-1770ijrcog20174398. 2017.
91.   Abdel-Aleem MA, Elkady MM, Hilmy YA. The relationship between female genital cutting and sexual problems experienced in the first two months of marriage. International Journal of Gynaecology & Obstetrics. 2016;132(3):305-8. PubMed PMID: 26686766.
92.   Yasin BA, Al-Tawil NG, Shabila NP, Al-Hadithi TS. Female genital mutilation among Iraqi Kurdish women: a cross-sectional study from Erbil city. BMC Public Health. 2013;13:809. PubMed PMID: 24010850.
93.   Saleem RA, Othman N, Fattah FH, Hazim L, Adnan B. Female genital mutilation in Iraqi Kurdistan: description and associated factors. Women & Health. 2013;53(6):537-51. PubMed PMID: 23937728.
94.   Adiguzel C, Bas Y, Erhan MD, Gelle MA. The Female Genital Mutilation/Cutting Experience in Somali Women: Their Wishes, Knowledge and Attitude. Gynecologic & Obstetric Investigation. 2019;84(2):118-27. PubMed PMID: 30227436.

95.	Dehghankhalili M, Fallahi S, Mahmudi F, Ghaffarpasand F, Shahrzad ME, Taghavi M, et al. Epidemiology, regional characteristics, knowledge, and attitude toward female genital mutilation/cutting in Southern Iran. Journal of Sexual Medicine. 2015;12(7):1577-83. doi: 10.1111/jsm.12938. PubMed PMID: 2015-33398-004.

96.	Makinde ON, Elusiyan JB, Adeyemi AB, Taiwo OT. FEMALE GENITAL MUTILATION: ARE WE WINNING? East African medical journal. 2012;89(6):193-8.

97.	Lawani LO, Onyebuchi AK, Iyoke CA, Okeke NE. Female genital mutilation and efforts to achieve Millennium Development Goals 3, 4, and 5 in southeast Nigeria. International Journal of Gynaecology & Obstetrics. 2014;125(2):125-8. PubMed PMID: 24602774.

98.	Minsart AF, N'Guyen T S, Ali Hadji R, Caillet M. Maternal infibulation and obstetrical outcome in Djibouti. Journal of Maternal-Fetal & Neonatal Medicine. 2015;28(14):1741-6. PubMed PMID: 25234101.

99.	Birge O, Arslan D, Ozbey EG, Adiyeke M, Kayar I, Erkan MM, et al. Which type of circumcision is more harmful to female sexual functions? Clinical and Experimental Obstetrics and Gynecology. 2017;44(5):691-4. doi: 10.12891/ceog3464.2017.

100.	Gudu W, Abdulahi M. Labor, Delivery and Postpartum Complications in Nulliparous Women with Female Genital Mutilation Admitted to Karamara Hospital. Ethiopian Medical Journal. 2017;55(1):11-7. PubMed PMID: 29148634.

101.	Sharfi AR, Elmegboul MA, Abdella AA. The continuing challenge of female genital mutilation in Sudan. African Journal of Urology. 2013;19(3):136-40. doi: 10.1016/j.afju.2013.06.002.

102.	Birge O, Serin AN, Bakir MS. Female genital mutilation/cutting in sudan and subsequent pelvic floor dysfunction. BMC Womens Health. 2021;21(1):8. doi: 10.1186/s12905-021-01576-y. PubMed PMID: WOS:000734775000006.

103.	Ashimi AO, Amole TG, Iliyasu Z. Prevalence and predictors of female genital mutilation among infants in a semi urban community in northern Nigeria. Sexual and Reproductive Healthcare. 2015;6(4):243-8. doi: 10.1016/j.srhc.2015.05.005.

104.	Korfker DG, Reis R, Rijnders ME, Meijer-van Asperen S, Read L, Sanjuan M, et al. The lower prevalence of female genital mutilation in the Netherlands: a nationwide study in Dutch midwifery practices. International Journal of Public Health. 2012;57(2):413-20. PubMed PMID: 22314540.

105.	Wahlberg A, Johnsdotter S, Selling KE, Kallestal C, Essen B. Baseline data from a planned RCT on attitudes to female genital cutting after migration: when are interventions justified? BMJ Open. 2017;7(8):e017506. PubMed PMID: 28801440.

106.	Shukralla HK, McGurgan P. Maternity care of women affected by female genital mutilation/cutting: An audit of two Australian hospitals. Women and Birth. 2020;33(4):E326-E31. doi: 10.1016/j.wombi.2019.07.008. PubMed PMID: WOS:000541401900003.

107.	Ukoha DE. Female genital mutilation/circumcision: Culture and women sexual health in lgbo women residing in Dallas-Fort Worth, Texas: ProQuest Information & Learning; 2016.

108.	Wikholm K, Mishori R, Ottenheimer D, Korostyshevskiy V, Reingold R, Wikholm C, et al. Female Genital Mutilation/Cutting as Grounds for Asylum Requests in the US: An Analysis of More than 100 Cases. Journal of Immigrant and Minority Health. 2020;22(4):675-81. doi: 10.1007/s10903-020-00994-8. PubMed PMID: WOS:000520809300001.

109.	Vrachnis N, Salakos N, Iavazzo C, Bakalianou K, Kouiroukidou P, Iliodromiti Z, et al. Female genital mutilation: A new reality for Greek healthcare providers. European Journal of Contraception and Reproductive Health Care. 2012;17:S129. doi: 10.3109/13625187.2012.673963.

110.	Zinka B, Ackermann I, Bormann C, Graw M. [Female genital mutilation in refugees]. MMW Fortschritte der Medizin. 2018;160(3):56-9. PubMed PMID: 29464617.

111.	Hänselmann K, Börsch C, Ikenberg H, Strehlau J, Klug SJ. Female genital mutilation in Germany. Geburtshilfe und Frauenheilkunde. 2011;71(3):205-8. doi: 10.1055/s-0030-1270887.

112.	Kartal YA, Yazici S. Female genital mutilation: Experiences, attitudes and perceptions of Somali female students living in Turkey. Perspect Psychiatr Care. 2021;57(4):1937-43. doi: 10.1111/ppc.12769. PubMed PMID: WOS:000631095500001.

113.   Frick A, Azuaga A, Abdulcadir J. Cervical dysplasia among migrant women with female genital mutilation/cutting type III: A cross-sectional study. Int J Gynecol Obstet. 2021:7. doi: 10.1002/ijgo.13921. PubMed PMID: WOS:000705333500001.

114.   Division of Sexual R, Child and Youth Health; Division of Health Statistics and Monitoring; Shared Services Ministry of Health (SPMS). Mutilação Genital Feminina Análise dos casos registados na PDS/RSE- PP 2014 - 2017. Government of Portugal, 2018.

115.   Davis G, Jellins J. Female genital mutilation: Obstetric outcomes in metropolitan Sydney. Australian & New Zealand Journal of Obstetrics & Gynaecology. 2019;59(2):312-6. PubMed PMID: 30734267.

116.   Johnson-Agbakwu CE, Fox KA, Banke-Thomas A, Michlig GJ. Influence of Female Genital Mutilation/Cutting on Health Morbidity, Health Service Utilization and Satisfaction with Care among Somali Women and Teenage Girls in the United States. J Racial Ethn Health Disparities. 2022:9. doi: 10.1007/s40615-022-01266-x. PubMed PMID: WOS:000766061800001.

117.   Michlig G, Warren N, Berhe M, Johnson-Agbakwu C. Female Genital Mutilation/Cutting among Somali Women in the US State of Arizona: Evidence of Treatment Access, Health Service Use and Care Experiences. International Journal of Environmental Research and Public Health. 2021;18(7):15. doi: 10.3390/ijerph18073733. PubMed PMID: WOS:000638497400001.

118.   Padovese V, Egidi AM, Melillo Fenech T, Podda Connor M, Didero D, Costanzo G, et al. Migration and determinants of health: clinical epidemiological characteristics of migrants in Malta (2010-11). Journal of Public Health. 2014;36(3):368-74. PubMed PMID: 24277779.

119.   Wahlberg A, Johnsdotter S, Ekholm Selling K, Essen B. Shifting perceptions of female genital cutting in a Swedish migration context. PLoS ONE [Electronic Resource]. 2019;14(12):e0225629. PubMed PMID: 31800614.

120.   Cottler-Casanova S, Horowicz M, Gayet-Ageron A, Abdulcadir J. Female genital mutilation/cutting (FGM/C) coding capacities in Swiss university hospitals using the International Classification of Diseases (ICD). Bmc Public Health. 2021;21(1):11. doi: 10.1186/s12889-021-11160-6. PubMed PMID: WOS:000664845500001.

121.   Rouzi AA, Berg RC, Sahly N, Alkafy S, Alzaban F, Abduljabbar H. Effects of female genital mutilation/cutting on the sexual function of Sudanese women: a cross-sectional study. American Journal of Obstetrics and Gynecology. 2017;217(1). doi: 10.1016/j.ajog.2017.02.044. PubMed PMID: WOS:000405276800015.

122.   Al Awar S, Al-Jefout M, Osman N, Balayah Z, Al Kindi N, Ucenic T. Prevalence, knowledge, attitude and practices of female genital mutilation and cutting (FGM/C) among United Arab Emirates population. BMC Womens Health. 2020;20(1):12. doi: 10.1186/s12905-020-00949-z. PubMed PMID: WOS:000529898100003.

123.   Zurynski Y, Phu A, Sureshkumar P, Cherian S, Deverell M, Elliott EJ, et al. Female genital mutilation in children presenting to Australian paediatricians. Archives of Disease in Childhood. 2017;102(6):509-15. PubMed PMID: 28082321.

124.   Varol N, Dawson A, Turkmani S, Hall JJ, Nanayakkara S, Jenkins G, et al. Obstetric outcomes for women with female genital mutilation at an Australian hospital, 2006-2012: a descriptive study. BMC Pregnancy & Childbirth. 2016;16(1):328. PubMed PMID: 27793119.

125.   Geynisman-Tan J, Milewski A, Dahl C, Collins S, Mueller M, Kenton K, et al. Lower Urinary Tract Symptoms in Women With Female Genital Mutilation. Female Pelvic Medicine & Reconstructive Surgery. 2019;25(2):157-60. PubMed PMID: 30807420.

126.   Chu T, Akinsulure-Smith AM. Health outcomes and attitudes toward female genital cutting in a community-based sample of West African immigrant women from high-prevalence countries in New York City. Journal of Aggression, Maltreatment & Trauma. 2016;25(1):63-83. doi: 10.1080/10926771.2015.1081663. PubMed PMID: 2016-08151-006.

127.   Castagna P, Ricciardelli R, Piazza F, Mattutino G, Pattarino B, Canavese A, et al. Violence against African migrant women living in Turin: clinical and forensic evaluation. International Journal of Legal Medicine. 2018;132(4):1197-204. PubMed PMID: 29308532.

128.   Ali S, Patel R, Armitage AJ, Learner HI, Creighton SM, Hodes D. Female genital mutilation (FGM) in UK children: a review of a dedicated paediatric service for FGM. Archives of Disease in Childhood. 2020;105(11):1075-8. doi: 10.1136/archdischild-2019-318336. PubMed PMID: WOS:000585987800012.

129.   Rouzi AA, Berg RC, Alamoudi R, Alzaban F, Sehlo M. Survey on female genital mutilation/cutting in Jeddah, Saudi Arabia. BMJ Open. 2019;9(5):e024684. PubMed PMID: 31154295.

130.   Creighton SM, Dear J, de Campos C, Williams L, Hodes D. Multidisciplinary approach to the management of children with female genital mutilation (FGM) or suspected FGM: service description and case series. BMJ Open. 2016;6(2):e010311. PubMed PMID: 26928027.

131.   Hodes D, Armitage A, Robinson K, Creighton SM. Female genital mutilation in children presenting to a London safeguarding clinic: a case series. Archives of Disease in Childhood. 2016;101(3):212-6. PubMed PMID: 26216833.

132.   Yoder PS, Wang S. Female genital cutting: the interpretation of recent DHS data. Calverton, Maryland, USA: ICF International, 2013.

133.   UNFPA. Female genital mutilation (FGM) frequently asked questions 2019. Available from: https://www.unfpa.org/resources/female-genital-mutilation-fgm-frequently-asked-questions Date Accessed: 22-04-2022.

134.   World Bank. Compendium of international and national legal frameworks on female genital mutilation 2021. Available from: https://openknowledge.worldbank.org/bitstream/handle/10986/35112/Compendium-of-International-and-National-Legal-Frameworks-on-Female-Genital-Mutilation-Fifth-Edition.pdf?sequence=1&isAllowed=y Date Accessed: 22-04-2022.

135.   FGM And The Law Around The World: Equality Now; 2019. Available from: https://www.equalitynow.org/the_law_and_fgm Date Accessed: 22-04-2022.

136.   Akinsulure-Smith AM, Sicalides EI. Female genital cutting in the United States: Implications for mental health professionals. Professional Psychology: Research and Practice. 2016;47(5):356-62. doi: 10.1037/pro0000079. PubMed PMID: 2016-39047-001.

137.   Ameyaw EK, Tetteh JK, Armah-Ansah EK, Aduo-Adjei K, Sena-Iddrisu A. Female genital mutilation/cutting in Sierra Leone: are educated women intending to circumcise their daughters? BMC international health and human rights. 2020;20(1):1-19. doi: 10.1186/s12914-020-00240-0.

138.   Ahinkorah BO. Factors associated with female genital mutilation among women of reproductive age and girls aged 0-14 in Chad: a mixed-effects multilevel analysis of the 2014-2015 Chad demographic and health survey data. BMC public health. 2021;21(1):286-. doi: 10.1186/s12889-021-10293-y.

139.   Female Genital Mutilation/Cutting: A statistical overview and exploration of the dynamics of change. 2013 23/12/2020. Report No.

140.   WHO. Female Genital Mutilation 2021. Available from: https://www.who.int/en/news-room/fact-sheets/detail/female-genital-mutilation Date Accessed 27-04-22.

141.   UNICEF. Calling for the end of the medicalization of female genital mutilation. 2018. Available from: https://www.unicef.org/sites/default/files/2019-02/Factsheet%20FGM-Medicalization-2018-06-15.pdf Date Accessed 27-04-22.

142.   Leye E, Van Eekert N, Shamu S, Esho T, Barrett H, Anser. Debating medicalization of Female Genital Mutilation/Cutting (FGM/C): learning from (policy) experiences across countries. Reproductive Health. 2019;16(1). doi: 10.1186/s12978-019-0817-3. PubMed PMID: WOS:000494464200002.

143.   Van Eekert N, Buffel V, De Bruyn S, Van de Velde S. The medicalisation of female genital cutting: Harm reduction or social norm? Sociology of health & illness. 2021;43(2):263-80. doi: 10.1111/1467-9566.13153.

144.   Elmusharaf S, Elhadi N, Almroth L. Reliability of self reported form of female genital mutilation and WHO classification: cross sectional study. BMJ. 2006;333(7559):124-7. Epub International edition. doi: 10.1136/bmj.38873.649074.55.

145.   Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34. doi: 10.1136/bmj.315.7109.629.

146.   Cappa C, Van Baelen L, Leye E. The practice of female genital mutilation across the world: Data availability and approaches to measurement. Global Public Health. 2019;14(8):1139-52. doi: 10.1080/17441692.2019.1571091.

147.   Tantet C, Aupiais C, Bourdon M, Sorge F, Pages A, Levy D, et al. Female genital mutilation: an evaluation of the knowledge of French general and specialized travel medicine practitioners. Journal of Travel Medicine. 2018;25(1):01. PubMed PMID: 29394392.

Table 1. Prevalence of Female Genital Mutilation/Cutting (FGM/C) in Women and Girls in Nationally Representative Studies

WHO Region	Country, Survey[§]	Year[§§]	Women 15-49 years			Girls 0-14 years[¶]		
			FGM/C, %	Total number with FGM/C	Sample Size	FGM/C, %	Total number with FGM/C	Sample Size
AFR	Benin, MICS [34]	2014	9.2	1,457	15,815	0.2	20	9,902
	Botswana, Pew study [†*] [31]	2010				5	20	399
	Burkina Faso, DHS [35]	2010	75.8	12,949	17,087	13.3	2,319*	17,434
	Cameroon, Pew study [†*] [31]	2010				1	8	755
	Central African Republic, MICS[36]	2018-2019	21.6	1,983	9,202	1.4	139	9,704
	Chad, MICS [37]	2019	34.1	7,698	22,561	7	1,838	26,303
	Chad, Pew study [†*][31]	2010				39	304	779
	Cote D'Ivoire, MICS [38]	2016	36.7	4,329	11,780	10.9	972	8,909
	Democratic Republic of Congo, Pew study [†*] [31]	2010				9	70	773
	Eritrea, Population and Health Survey [†*][32]	2010	82.9	8,495	10,238	44.1	2,409	5,461
	Ethiopia, DHS [39]	2016	65.2	5,101	7,822	15.7	1,147	7,306
	Ethiopia, Pew study [†*] [31]	2010				33	204	618
	Gambia, DHS[40]	2021	72.6	4,490	6,186	45.9	2,343	5,105
	Ghana, MICS [41]	2018	2.4	341	14,374	0.1	15	12,015
	Ghana, Pew study [†*] [31]	2010				9	63	699[†]
	Guinea, DHS[42]	2018	94.5	10,276	10,874	39.1	3,563	9,122
	Guinea Bissau, MICS [43]	2020	52.1	5,703	10,945	29.7	2,558	8,625
	Guinea-Bissau, Pew study[†*][31]	2010				33	178	539
	Kenya, DHS[44]	2014	21	3,066	14,625	2.8	352	12,388
	Kenya, Pew study [†*][31]	2010				10	76	762
	Liberia, DHS [45] [#]	2021	38.2	2,568	6,716			
	Liberia, Pew study [†*][31]	2010				21	182	866
	Mali, DHS [46]	2018	88.6	4,699	5,302	72.7	4,314	5,939
	Mali, Pew study [†*] [31]	2010				77	447	581
	Mauritania, MICS [47]	2015	66.6	9,555	14,342	53.2	6,936	13,048
	Mozambique, Pew study [†*][31]	2010				12	76	631
	Niger, DHS[49]	2012	2	219	11,160			
	Nigeria, DHS [48]	2018	19.5	5,202	26,705	19.2	4,640	24,143
	Nigeria, Pew study [†*] [31]	2010				13	106	813
	Rwanda, Pew study [†*][31]	2010				3	15	499
	Senegal, DHS[50]	2019	25.2	2,181	8,649	16.1	1,176	7,288
	Senegal, Pew study [†*][31]	2010				4	21	537
	Sierra Leone, DHS[51]	2019	83	12,932	15,574	7.9	946	12,037

	Year	Women prevalence	Women number with FGM/C	Women total population	Girls prevalence	Girls number with FGM/C	Girls total population
South Africa, Pew study †* [31]	2010				4	33	819
Tanzania, DHS [52]	2016	10	1,329	13,266	0.4	47	11,795
Tanzania, Pew study †*[31]	2010				6	64	1,074
Togo, MICS [53]	2017	3.1	225	7,326	0.3	17	6,077
Uganda, DHS[54]	2016	0.3	56	18,506			
Uganda, Pew study †* [31]	2010				13	89	682
Zambia, Pew study †* [31]	2010				3	13	443
EMR Djibouti, Pew study †* [31]	2010				58	469	808
Egypt, DHS ¶¶[55]	2014	92.3	20,086*	21,762	21.4	4,941*	23,090
Iraq, MICS [56]	2018	7.4	2,270	30,660	0.5	128	24,438
Somalia, DHS[58]	2020	99.2	14,651	14,771	33.3#	2,492#	7,482#
Sudan, MICS [57]	2014	86.6	15,853	18,302	31.5	5,570	17,661
Yemen, DHS †* [33]	2013	18.5	4,705	25,434	15.9†	1,909	12,005
SEAR Maldives, DHS [59]	2016-2017	12.9	996	7,699	1.1	40*	3,626
Indonesia, RISKESDAS ††[30]	2013				51.2	NA	NA

	Women 15-49 years			Girls 0-14 years¶¶		
Pooled prevalence ‡	Pooled prevalence, % (95% CI)	Estimated total number with FGM/C (95% CI)	Total population Ŧ	Pooled prevalence, % (95% CI)	Estimated total number with FGM/C (95% CI)	Total population Ŧ
Global	38.31 (20.8-59.5)	86,080,915 (46,736,701 - 133,693,929)	224,695,680	7.25 (3.1-16.0)	11,982,031 (5,123,351 - 26,476,156)	165,269,394
AFR	32.01 (16.2-53.5)	53,533,504 (28,096,309 - 89,406,470)	167,239,938	7.14 (2.7-17.8)	9,193,035 (3,424,856 - 22,905,335)	128,753,992
EMR	73.68 (21.0-96.7)	42,249,544 (12,041,808 - 56,034,547)	57,341,944	12.02 (2.1-46.7)	4,382,987 (762,100 – 17,014,158)	36,464,121

Abbreviations: AFR: African Region; DHS: Demographic and Health Survey; EMR: Eastern Mediterranean Region; MICS: Multiple Indicator Cluster Surveys; NA: Not available; SEAR: South-East Asia Region; WHO: World Health Organization.
§The Pew study corresponds to the Islam & Christianity in Sub-Saharan Africa Survey, Pew Research Centre.
§§Year of data collection
¶For girls, studies are either reporting (1) the percentage/total number of girls with FGM/C or (2) the percentage/total number of women with at least one daughter with FGM/C.
¶¶In the Egypt DHS 2014 report, the age category of girls is 0 to 19 years.
* The total number with FGM/C was computed using data available in the study/report.
† Excluded from the meta-analyses of girls (0-14 years) as results represent the percentage of women with at least one daughter with FGM/C [31-33]
††Excluded from the meta-analyses of girls (0-14 years) due to insufficient data.
‡No pooled prevalence was calculated for SEAR as data were only available from one country.
Ŧ Population estimates were taken from the United Nations 2019 Revision of World Population Prospects total population estimates for 2020 [29].
#This computed using the dataset as no denominator was provided in the report. #Liberia: among women who have heard of FGM/C.

Table 2. Repeated nationally representative cross-sectional studies reporting the prevalence of Female Genital Mutilation/Cutting (FGM/C) by country

Region	Country	Date of survey	% FGM/C amongst women	Total sample size of women	% FGM/C amongst girls	Total sample size of girls	Survey source
AFR	Benin	2001*	17.0	6,219			DHS
		2006*	12.9	17,793			
		2011-2012	7.3	16,599	0.3	10,671	
		2014	9.2	15,815	0.2	9,902	MICS
	Botswana	2010*			5.0	399	Pew Res Center
	Burkina Faso	1998-1999**	71.6	6,445	45.5	3,499	DHS
		2003*	76.6	12,477	31.6	7,540	
		2006*	72.5	7,316	24.7	4,548	MICS
		2010	75.8	17,087	13.3	17,434	DHS
	Cameroon	2004*	1.4	5,391	0.7	2,975	DHS
		2010*			1.0	755	Pew Res Center
	Central African Republic	1994-95	43.4	5,884			DHS
		2000	35.9	16,941			
		2006*	25.7	11,592	6.6	6,778	MICS
		2010	24.2	11,510	0.8	17,441	
		2018-2019	21.6	9,202	1.4	9,704	
	Chad	2004*	44.9	6,085	20.7	3 893	DHS
		2010	44.2	15,936	12.1	15,936	MICS
		2010*			39.0	779	Pew Res Center
		2014-2015	38.4	11,534	9.9	14,310	DHS
		2019	34.1	22,561	7.0	26,303	MICS
	Côte D'Ivoire	1998-99**	44.5	3,040	25.8	1595	DHS
		2005	41.7	5,183			AIS
		2006	36.0	12,888	9.5		MICS
		2011-2012	38.2	10,060	10.5	8,110	DHS
		2016	36.7	11,780	10.9	8,090	MICS
	Democratic Republic of Congo	2010*			9.0	773	Pew Res Center
	Eritrea	1995**	94.5	5,054	71.4		DHS
		2002*	88.7	8,754	62.5	4,604	
	Ethiopia	2000*	79.9	15,367	51.9	7,659	
		2005*	74.3	14,070	37.7	7,920	DHS
		2010*			33.0	618	Pew Res Center
		2016	65.2	7,822	15.7	7,306	DHS
	Gambia	2005-2006*	78.3	9,982	64.3	5,337	MICS
		2010	76.3	14,685	42.4	16,635	
		2013	74.9	10,233			DHS
		2018	75.7	13,64	50.6	11,718	MICS
		2019-2020	72.6	6,186	45.9	5,105	DHS
	Ghana	2006	3.8	5,890			MICS
		2010*			9.0	699	Pew Res Center
		2011	3.8	10,627	0.4	8,276	MICS
		2017-2018	2.4	14,374	0.1	12,015	
	Guinea	1999*	98.6	6,753	54.4	4,240	
		2005*	95.6	7,954	56.8	4,972	DHS
		2012	96.9	9,142	45.5	8,497	
		2016	96.8	9,663	45.3	8,832	MICS
		2018	94.5	10 874	39.1	9 ,122	DHS
	Guinea Bissau	2006*	44.5	8,010	34.7	4,575	MICS
		2010*	49.8	18,734	38.7	10,563	
		2010*			33.0	539	Pew Res Center
		2014	44.9		29.6		MICS
		2018-2019	52.1	10,945	29.7	8,625	
	Kenya	1998**	37.6	7,881	24.1	1,590	DHS

Country	Year					Source
	2003**	32.2	8,195	21.0	1,577	
	2008-2009	27.1	8,444			
	2010*			10.0	762	Pew Res Center
	2014	21.0	14,625	2.8	12,388	DHS
Liberia	2010*			21.0	866	Pew Res Center
	2019-2020[†]	38.2	6,716			
Mali	1995-1996**	93.7	9,704	73.6	6,399	DHS
	2001	91.6	12,849	73.0	8,223	
	2006*	85.2	14,583	68.7	9,105	
	2009-2010*	88.5	26,751	74.6		MICS
	2010*			77.0	581	Pew Res Center
	2012-2013	91.4	10,424	69.2	11,857	DHS
	2015	82.7		76.4		MICS
	2018	88.6	5,302	72.7	5 939	DHS
Mauritania	2000-2001*	71.3	7,728	66.2	3,887	DHS
	2007*	72.2	12,549	65.8	6,454	MICS
	2011	69.4	12,754	54.8	10,992	
	2015	66.6	14,342	53.2	13,048	
Mozambique	2010*			12.0	631	Pew Res Center
Nigeria	1999**	25.1	8,206	20.2	4,503	DHS
	2003*	19.0	7,620	9.9	4,129	
	2007*	26.0	24,565	13.3	13,124	MICS
	2008*	29.6	33,385	29.9	11,563	DHS
	2010*			13.0	813	Pew Res Center
	2011	27.0	30,772	19.2	16,874	MICS
	2013	24.8	38,948	16.9	36,308	DHS
	2016-2017	18.4	34,376	25.3	17,529	MICS
	2018	19.5	26,705	19.2	24,143	DHS
Niger	1998*	4.5	7,577	2.5		DHS
	2006*	2.2	9,223	0.9	6,173	DHS
	2012	2.0	11,160			
Rwanda	2010*			3.0	499	Pew Res Center
Senegal	2005*	28.2	14,602	19.5	7,419	
						DHS
	2010*			4.0	537	Pew Res Center
	2010-2011	25.7	15,688	12.9	8,983	DHS
	2012-2013			17.5	7,172	
	2014	24.7	8,488	12.9	7,186	
	2015	24.2	8,851	14.6	7,529	
	2016	22.7	8,865	13.6	7,390	
	2017	24.0	16,787	14.0	14,008	
	2018	23.3	9,414	14.1	7,598	
	2019	25.2	8 649	16.1	7 288	
Sierra Leone	2008*	91.3	7,374	32.5	4,590	DHS
	2010	88.3	13,359	10.2	14,703	MICS
	2013	89.6	16,658			DHS
	2017	86.1	17,873	8.4	12,972	MICS
	2019	83.0	15,574	7.9	12,037	DHS
South Africa	2010*			4.0	819	Pew Res Center
United Republic of Tanzania	1996**	17.9	8,120	6.7	4,753	DHS
	2003-2004	17.7	6,863			
	2004-2005*	14.6	10,329	4.2	6,095	
	2010*	14.6	10,139	3.4	6,075	
	2010*			6.0	1074	Pew Res Center
	2015-2016	10.0	13,266	0.4	11,795	DHS
Togo	2006*	5.8	6,211	1.0	3,431	MICS

Region	Country	Year					Source
		2010	3.9	6,379	0.4	4,679	
		2013-2014	4.7	9,480	0.3		DHS
		2017	3.1	7,326	0.3	6,077	MICS
	Uganda	2006	0.6	8,531			DHS
		2010*			13.0	682	Pew Res Center
		2011	1.4	8,674			DHS
		2016	0.3	18,506			
	Zambia	2010*			3.0	443	Pew Res Center
EMR	Egypt	1995*	97.0	14,779	49.7	10,847	DHS
		2000*	97.3		49.5	11,540	
		2003*	97.0	9159	47.3	6,587	
		2005	95.8	19,474	27.7	20,628	
		2008	91.1		24.1	16,475	
		2014	92.3	21,762	21.4	23,090	
		2015	87.2	7,906	14.1	5,280	
	Djibouti	2006*	93.1	6,020	48.5	1,923	MICS
		2010*			58.0	808	Pew Res Center
	Iraq	2011	8.1	55,194	20.6	8,759	MICS
		2018	7.4	30,660	0.5	24,438	
	Somalia	2006*	97.9	6,764	46.0	3,716	MICS
		2020	99.2	14,771	33.3#	7,482#	DHS
	Sudan	1989-1990	89.2	5,860			DHS
		2010	88.2¶	16,716	37.0	19,084	MICS
		2014	86.6	18,302	31.5	17,661	
	Yemen	1997*	22.6	10,414	19.7	7,854	DHS
		2013*	18.5	25,434	15.9	12,005	
SEAR	Indonesia	2013			51.2		RISKESDAS
	Maldives	2016-2017	12.9	7,699	1.1	3,626	DHS

Abbreviations: AFR: African Region; DHS: Demographic and Health Survey; EMR: Eastern Mediterranean Region; MICS: Multiple Indicator Cluster Surveys; Empty cell: Not available in report; SEAR: South-East Asia Region. *Women with at least one living daughter with FGM/C. **Women reporting whether their eldest daughter had FGM/C. ¶Age range for women 18-49 years old. †Among women who have heard of FGM/C #This was computed using the dataset as no denominator was provided in the report. For most countries girls was defined as 0-14 years old; Indonesia (2013) 0-11 years old; Senegal (2010-11) 0-9 years; Egypt (2015) age 1-14 years old; Egypt (2014) 0-19 years old; Egypt (2008 & 2005) 0-17 years old.

Table 3. Types of Female Genital Mutilation/Cutting (FGM/C) in Nationally Representative Studies

WHO Region	Country, Survey	Year[§]	Women 15-49 years					Girls 0-14 years					
			Prevalence FGM/C, n (%)	Type of FGM/C, % [§§]				Prevalence FGM/C, n (%)	Type of FGM/C, % [§§]				
				Nicked	Flesh removed	Sewn closed	Don't Know/ Missing Type		Nicked	Not Sewn Closed	Flesh removed	Sewn closed	Don't Know/ Missing Type
AFR	Benin, MICS[34]	2014	1,457 (9.2)	14.5	72.1	10.1	3.4	20 (0.2)					
	Burkina Faso, DHS[35]	2010	12,949 (75.8)	16.6	76.8	1.2	5.4	2,319 (13.3)					
	Central African Republic, MICS[36]	2018-2019	1,983 (21.6)	0.8	47.6	49.6	2	139 (1.4)	0.2		38.6	59.2	2.0
	Chad, MICS[37]	2019	7,698 (34.1)	5.5	71.9	15.8	6.8	1,838 (7.0)	4.4		73.6	18.5	3.5
	Cote D'Ivoire, MICS[38]	2016	4,329 (36.7)	6.8	63.3	9.4	20.5	972 (10.9)	6.3		78.4	10.4	4.9
	Ethiopia, DHS [39]	2016	5,101 (65.2)	2.6	73	6.5	17.9	1,147 (15.7)		90.1		9.3	0.6
	Gambia, DHS[40]	2021	4,490 (72.6)	1.4	73.4	16.6	8.7	2,343 (45.9)		67.8		15.2	17.1
	Ghana, MICS [41]	2018	341 (2.4)	4.6	63.6	15.9	15.9	15 (0.1)			74.5	20.2	5.2
	Guinea, DHS[42]	2018	10,276 (94.5)	11	57.7	9.7	21.6	3,563 (39.1)		84.2		15.8	
	Guinea Bissau, MICS[43]	2020	5,703 (44.5)	1.1	73.8	18.5	6.5	2,558 (29.7)	1.5		84.1	13.4	3.6
	Kenya, DHS[44]	2014	3,066 (21)	1.6	87.2	9.3	1.9	352 (2.8)		86.3		7.8	5.9
	Mali, DHS[46]	2018	4,699 (88.6)	25.4	40.7	8.2	25.8	4,314 (72.7)		88.6		11.4	
	Mauritania, MICS[47]	2015	9,555 (66.6)	1.2	64.9	4.5	29.4	6,936 (53.2)	1.0		75.2	4.2	19.6
	Niger, DHS[49]	2012	219 (2.0)	7.2	78.4	6.3	8.1						
	Nigeria, DHS[48]	2018	5,202 (19.5)	9.6	40.7	5.6	44.1	4,640 (19.2)		96.5		3.5	
	Senegal, DHS[50]	2019	2,181(25.2)	9.2	57.7	9.1	24.0	1,176 (16.1)		84.3		5.1	10.6
	Sierra Leone, DHS[51]	2020	12,932 (83.0)	0.7	84	11.9	3.3	946 (7.9)		83.3		15.9	0.8
	Tanzania, DHS [52]	2016	1,329 (10.0)	3.2	81.1	6.6	9.1						
	Togo, MICS[53]	2017	225 (3.1)	6.3	54	36.2	3.5						
EMR	Iraq, MICS[56]	2018	2,270 (7.4)	6	84.3	1.3	8.4	128 (0.5)	9.1		88.8	1.0	1.1
	Somalia, DHS[58]	2020	14,651 (99.2)		33.9[¶]	64.2[¶]	1.9						
	Sudan, MICS [57]	2014	15,853 (86.6)	2.2	16.3	77	4.5	5,570 (31.5)					
	Yemen, DHS[33]	2013	4,705(18.5)	7	89.7	NA	3.3	1,909 (15.9)[†]	10.7[††]	88.3[††]			1.0[††]

Abbreviations: AFR: African Region; DHS: Demographic and Health Survey; EMR: Eastern Mediterranean Region; MICS: Multiple Indicator Cluster Surveys; WHO: World Health Organization.

[§]Year of data collection

§§ Percentages of types from women and girls are calculated from the total number of women and girls with FGM/C, respectively
¶ Type I, Sunni= 21.6% and Type II, Intermediate = 12.3%
¶¶ Type III and IV= 64.2%
† Prevalence and total number with FGM/C correspond to those of women with at least one daughter with FGM/C.
†† Percent distribution of most recent daughters who had FGM/C

Table 4. Characteristics of Female Genital Mutilation/Cutting (FGM/C) Procedure in Nationally Representative Studies

WHO Region	Country, Survey	Year[§]	Percent distribution of women 15-49 years by:		Percent distribution of girls 0-14 years by:	
			Age at FGM/C (%)	Performer of FGM (%)	Age at FGM/C (%)	Performer of FGM (%)
AFR	Burkina Faso, DHS[35]	2010	<5y (60.4%), 5-9y (28.2%), 10-14y (8.9%), 15+y (2.0%), Don't know/missing (0.5%)	Traditional (97.2%) Medical (0.2%) Don't know/missing (2.6%)	<1y (2.8%), 1-4y (7.3%), 5-9y (3.1%), 10-14y (0.1%), Don't know/missing (0.1%)	Traditional (98.3%) Medical (0.2%) Don't know/missing (1.5%)
	Eritrea, Population and Health Survey [32]	2010	<1y (47.4%), 1-3y (4.7%)	Traditional (84.4%) Medical (0.3%) Other (15.4%)	<1y (65.7%), 1-4y (20.9%), 5-6y (8.1%), 7-8y (4.3%), 9-10y (0.4%), 11-12y (0.1%) 13+y (0.1%), Don't know/missing (0.4%)	Traditional (98.3%) Medical (0.09%) Don't know/missing (1.6%)
	Ethiopia, DHS [39]	2016	<5y (48.6%), 5-9y (21.7%), 10-14y (18.0%), 15+y (5.9%), Don't know/missing (5.8%)	Traditional (90.1%) Medical (1%) Don't know/missing (8.9%)	<1y (7.2%), 1-4y (3.4%), 5-9y (3.7%), 10-14y (1.0%), Don't know/missing (0.3%)	Traditional (97.6%) Medical (1.9%) Don't know/missing (0.5%)
	Kenya, DHS [44]	2014	<5y (2.3%), 5-9y (26.6%), 10-14y (42.6%), 15+y (26.9%), Don't know /missing (1.7%)	Traditional (83.3%) Medical (14.8%) Don't know/missing (1.9%)	<1y (0.0%), 1-4y (0.2%) 5-9y (2.1%), 10-14y (0.5%)	Traditional (74.9%), Medical (19.7%) Don't know/missing (5.4%).
	Mali, DHS [46]	2018	<5y (75.5%), 5–9y (16.1%), 10-14y (4.4%). 15+y (0.3%), Don't know missing (3.6%)	Traditional (91.5%) Medical (0.3%) Don't know/missing (8.2%)	<1y (34.2%), 1-4y (31.9%), 5-9 (5.2%), 10-14y (0.4%), Don't know/missing (0.9%)	Traditional (98.6%) Medical (1.4%)
	Nigeria, DHS [48]	2018	<5y (85.6%), 5-9y (4.2%), 10-14y (3.9%), 15+y (4.5%), Don't know/missing (1.8%)	Traditional (85.4%) Medical (8.6%) Don't know/missing (6%)	<1y (17.2%), 1-4y (1.1%), 5-9 (0.7%), 10-14y (0.0%), Don't know/missing (0.1%)	Traditional (92.8%) Medical (7%) Don't know/missing (0.1%)
	Niger, DHS[49]	2012	<5y (75.7%), 5-9y (7.3%), 10-14y (7.9%), 15+y (1.4%), Don't know/missing (7.8%)	Traditional (95.8%) Other (0.2%) Don't know/missing (4%)		
	Senegal, DHS [50]	2019	<5y (84.9%), 5-9y (10.4%), 10-14y (2.7%), 15+y (0.4%), Don't know /missing (1.7%)	Traditional (100%)	<1y (9.8%), 1-4y (5.4%), 5-9y (0.8%), 10-14y (0.0%), Don't know/missing (0.1)	Traditional (100%)
	Sierra Leone, DHS [51]	2019	<5y (12.3%), 5-9y (14.1%), 10-14y (44.9%), 15+y (26.1%), Don't know /missing (2.5%)	Traditional (98.4%) Medical (0.4%) Don't know/missing (1.2%)	< 1y (0.0%), 1-4y (0.6%), 5-9y (4.1%), 10-14y (3.1%), Don't know/missing (0.1%)	Traditional (99.4%) Medical (0.6%)
	Guinea, DHS[42]	2018	<5y (22.4%), 5-9y (36.7%), 10-14y (28.4%), 15+y (3.9%), Don't know/missing (8.6%)	Traditional (77.6%) Medical (17.3%) Don't know/missing (5.1%)	<1y (1.5%), 1-4y (11.9%), 5-9y (22.7%), 10-14y (2.3%), Don't know/missing (0.8%)	Traditional (64.8%) Medical (34.9%) Don't know/missing (0.3%)
	Liberia, DHS[45]	2020	<5y (24.6%), 5-9y (16.7%), 10-14y (33%), 15+y (21.6%), Don't know (4.1%)			
	Gambia, DHS[40]	2021	<5y (64.9%), 5-9y (17.7%), 10-14y (6%), 15+y (0.7%), Don't	Traditional (95.1%) Medical (0.4%)	<1y (21.9%), 1-4y (19.4%), 5-9y (3.9%), 10-14y (0.2%), Don't know	Traditional (98.8%) Medical (0.1%),

		Year§				
			know /missing (10.6%)	Don't know/missing (4.5%)	(4.5%)	Don't know/missing (1.1%)
	Tanzania, DHS[52]	2016	<1y (35.4%), 1-4y (2.3%), 5-6y (5.2%), 7-8y (7.5%), 9-10y (10.9%), 11-12y (9.3%), 13+y (27.6%), Don't know/missing (1.8%)	Traditional (86%) Medical (14.8%) Don't know/missing (1.9%)	<1y (0.1%), 1-4y (0.2%), 5-9y (0.1%), 10-14y (0.1%)	Traditional (74.9%) Medical (19.7%) Don't know/missing (5.4%)
EMR	Egypt, DHS[55]	2014	<3y (0.6%), 3-4y (1%), 5-6y (7.4%), 7-8y (13.4%), 9-10y (40.9%) 11-12y (24.6%), 13-14y (5.3%), 15-17y (2.6%), 18-19y (0.1%), Don't know/missing (4.2%)	Traditional (60.5%) Medical (37.9%) Other (0.1%), Don't know/missing (1.5%)	<3 y (3.5%); 3-4y (3.4%), 5-6y (10.1%), 7-8y (14.1%), 9-10y (32.8%) 11-12y (28.6%), 13-14y (5.4%), 15-17y (1.3%), Don't know /missing (0.7%)	Medical (81.9%) Traditional (18.1%) Don't know/missing (0.3%)
	Somalia, DHS [58]	2020	<5y (0.2%), 5-9y (70.9%), 10-14y (27.7%), 15+y (0.7%), Don't know /missing (0.5%)		0-4y (3.3%), 5-9y (29.7%), 10-14y (75.9%)	
	Yemen, DHS [33]	2013	First week after birth (83.8%), after first week but before first year (10.5%), >=1y (1.2%), Don't know /missing (4.5%)	Traditional (92.8%) Medical (2.9%) Don't know/missing (4.3%)	First week after birth (84.9%), after 1st week but before 1 year (14.3%), >=1y (0.6%), Don't know/missing (0.2%)	Traditional (84.7%) Medical (12.8%) Don't know/missing (2.5%)
SEAR	Indonesia, RISKESDAS [30]	2013			1-5 months (72.4%), 1-4y (13.9%), 5-11 y (3.3%)	
	Maldives, DHS[147]	2016-2017	<5y (83.1%), 5-9y (1.6%), 10-14y (0.4%), 15+y (0.4%), Don't know/missing (14.5%)		<1y (0.7%), 1-4y (0.2%), Don't know/missing (0.1%)	

Abbreviations: AFR: African Region; DHS: Demographic and Health Survey; EMR: Eastern Mediterranean Region; MICS: Multiple Indicator Cluster Surveys; WHO: World Health Organization; y: years.
§Year of data collection

PRISMA Flow Diagram

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

Study		Proportion	95%-CI
DHS 2020 - Somalia		0.99	[0.99; 0.99]
DHS 2019 - Guinea		0.95	[0.94; 0.95]
DHS 2015 - Egypt		0.92	[0.92; 0.93]
DHS 2019 - Mali		0.89	[0.88; 0.89]
MICS 2016 - Sudan		0.87	[0.86; 0.87]
DHS 2020 - Sierra Leone		0.83	[0.82; 0.84]
Population and Health Survey 2013 - Eritrea		0.83	[0.82; 0.84]
DHS 2012 - Burkina Faso		0.76	[0.75; 0.76]
DHS 2021 - Gambia		0.73	[0.71; 0.74]
MICS 2017 - Mauritania		0.67	[0.66; 0.67]
DHS 2017 - Ethiopia		0.65	[0.64; 0.66]
MICS 2020 - Guinea Bissau		0.52	[0.51; 0.53]
DHS 2021 - Liberia		0.38	[0.37; 0.39]
MICS 2017 - Cote D'Ivoire		0.37	[0.36; 0.38]
MICS 2021 - Chad		0.34	[0.34; 0.35]
DHS 2020 - Senegal		0.25	[0.24; 0.26]
MICS 2021 - Central African Republic		0.22	[0.21; 0.22]
DHS 2015 - Kenya		0.21	[0.20; 0.22]
DHS 2019 - Nigeria		0.19	[0.19; 0.20]
DHS 2015 - Yemen		0.18	[0.18; 0.19]
DHS 2018 - Maldives		0.13	[0.12; 0.14]
DHS 2016 - Tanzania		0.10	[0.10; 0.11]
MICS 2015 - Benin		0.09	[0.09; 0.10]
MICS 2018 - Iraq		0.07	[0.07; 0.08]
MICS 2018 - Togo		0.03	[0.03; 0.03]
MICS 2018 - Ghana		0.02	[0.02; 0.03]
DHS 2013 - Niger		0.02	[0.02; 0.02]
DHS 2018 - Uganda		0.00	[0.00; 0.00]
Random effects model		**0.38**	**[0.21; 0.60]**
Prediction interval			**[0.00; 0.99]**

Heterogeneity: $I^2 = 100\%$, $\tau^2 = 5.4019$, $p = 0$

0.2   0.4   0.6   0.8

Study		Proportion	95%-CI
DHS 2019 - Mali		0.73	[0.71; 0.74]
MICS 2017 - Mauritania		0.53	[0.52; 0.54]
DHS 2021 - Gambia		0.46	[0.45; 0.47]
DHS 2019 - Guinea		0.39	[0.38; 0.40]
SDHS 2020 - Somalia		0.33	[0.32; 0.34]
MICS 2016 - Sudan		0.33	[0.32; 0.33]
MICS 2020 - Guinea Bissau		0.30	[0.29; 0.31]
DHS 2015 - Egypt		0.21	[0.21; 0.22]
DHS 2019 - Nigeria		0.19	[0.19; 0.20]
DHS 2020 - Senegal		0.16	[0.15; 0.17]
DHS 2017 - Ethiopia		0.16	[0.15; 0.17]
DHS 2012 - Burkina Faso		0.13	[0.13; 0.14]
MICS 2017 - Cote D'Ivoire		0.11	[0.10; 0.12]
DHS 2020 - Sierra Leone		0.08	[0.07; 0.08]
MICS 2021 - Chad		0.07	[0.07; 0.07]
DHS 2015 - Kenya		0.03	[0.03; 0.03]
MICS 2021 - Central African Republic		0.01	[0.01; 0.02]
MICS 2019 - Iraq		0.01	[0.00; 0.01]
DHS 2018 - Maldives		0.01	[0.01; 0.01]
DHS 2016 - Tanzania		0.00	[0.00; 0.01]
MICS 2018 - Togo		0.00	[0.00; 0.00]
MICS 2015 - Benin		0.00	[0.00; 0.00]
MICS 2018 - Ghana		0.00	[0.00; 0.00]
Random effects model		**0.07**	**[0.03; 0.16]**
Prediction interval			**[0.00; 0.89]**

Heterogeneity: $I^2 = 100\%$, $\tau^2 = 4.7567$, $p = 0$

0.2   0.4   0.6   0.8

Study	Proportion	95%-CI
DHS 2019 - Nigeria	0.63	[0.62; 0.64]
DHS 2019 - Mali	0.25	[0.24; 0.27]
DHS 2012 - Burkina Faso	0.17	[0.16; 0.17]
MICS 2015 - Benin	0.14	[0.13; 0.16]
DHS 2019 - Guinea	0.11	[0.10; 0.12]
DHS 2020 - Senegal	0.09	[0.08; 0.11]
DHS 2013 - Niger	0.07	[0.04; 0.12]
DHS 2015 - Yemen	0.07	[0.06; 0.08]
MICS 2017 - Cote D'Ivoire	0.07	[0.06; 0.08]
MICS 2018 - Togo	0.06	[0.03; 0.10]
MICS 2018 - Iraq	0.06	[0.05; 0.07]
MICS 2021 - Chad	0.06	[0.05; 0.06]
MICS 2018 - Ghana	0.05	[0.03; 0.08]
DHS 2017 - Ethiopia	0.03	[0.02; 0.03]
DHS 2016 - Tanzania	0.03	[0.02; 0.04]
MICS 2016 - Sudan	0.02	[0.02; 0.02]
DHS 2015 - Kenya	0.02	[0.01; 0.02]
MICS 2017 - Mauritania	0.01	[0.01; 0.01]
DHS 2021 - Gambia	0.01	[0.01; 0.02]
MICS 2020 - Guinea Bissau	0.01	[0.01; 0.01]
DHS 2020 - Sierra Leone	0.01	[0.01; 0.01]
MICS 2021 - Central African Republic	0.01	[0.00; 0.01]
Random effects model	**0.05**	**[0.03; 0.08]**

Heterogeneity: $I^2 = 100\%$, $\tau^2 = 1.6821$, $p = 0$

0.1 0.2 0.3 0.4 0.5 0.6

Study		Proportion	95%-CI
DHS 2015 - Yemen		0.90	[0.89; 0.91]
DHS 2015 - Kenya		0.87	[0.86; 0.88]
MICS 2018 - Iraq		0.84	[0.83; 0.86]
DHS 2020 - Sierra Leone		0.84	[0.83; 0.85]
DHS 2016 - Tanzania		0.81	[0.79; 0.83]
DHS 2013 - Niger		0.79	[0.73; 0.84]
DHS 2012 - Burkina Faso		0.77	[0.76; 0.78]
MICS 2020 - Guinea Bissau		0.74	[0.73; 0.75]
DHS 2021 - Gambia		0.73	[0.72; 0.75]
DHS 2017 - Ethiopia		0.73	[0.72; 0.74]
MICS 2021 - Chad		0.72	[0.71; 0.73]
MICS 2014 - Benin		0.72	[0.70; 0.74]
MICS 2017 - Mauritania		0.65	[0.64; 0.66]
MICS 2018 - Ghana		0.64	[0.58; 0.69]
MICS 2017 - Cote D'Ivoire		0.63	[0.62; 0.65]
DHS 2019 - Guinea		0.58	[0.57; 0.59]
DHS 2020 - Senegal		0.58	[0.56; 0.60]
MICS 2018 - Togo		0.54	[0.47; 0.60]
MICS 2021 - Central African Republic		0.48	[0.45; 0.50]
DHS 2019 - Mali		0.41	[0.39; 0.42]
DHS 2019 - Nigeria		0.41	[0.39; 0.42]
DHS 2020 - Somalia		0.22	[0.21; 0.22]
MICS 2016 - Sudan		0.16	[0.16; 0.17]
Random effects model		**0.66**	**[0.57; 0.74]**

Heterogeneity: $I^2 = 100\%$, $\tau^2 = 0.8736$, $p = 0$

0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9

Study		Proportion	95%-CI

	Proportion	95%-CI
MICS 2016 - Sudan	0.77	[0.76; 0.78]
DHS 2021 - Somalia	0.64	[0.63; 0.65]
MICS 2021 - Central African Republic	0.50	[0.47; 0.52]
MICS 2018 - Togo	0.36	[0.30; 0.43]
MICS 2020 - Guinea Bissau	0.18	[0.17; 0.20]
DHS 2021 - Gambia	0.17	[0.16; 0.18]
MICS 2018 - Ghana	0.16	[0.12; 0.20]
MICS 2021 - Chad	0.16	[0.15; 0.17]
DHS 2020 - Sierra Leone	0.12	[0.11; 0.12]
DHS 2019 - Guinea	0.10	[0.09; 0.10]
MICS 2015 - Benin	0.10	[0.09; 0.12]
MICS 2017 - Cote D'Ivoire	0.09	[0.09; 0.10]
DHS 2015 - Kenya	0.09	[0.08; 0.10]
DHS 2020 - Senegal	0.09	[0.08; 0.10]
DHS 2019 - Mali	0.08	[0.07; 0.09]
DHS 2016 - Tanzania	0.07	[0.05; 0.08]
DHS 2017 - Ethiopia	0.07	[0.06; 0.07]
DHS 2013 - Niger	0.06	[0.04; 0.10]
DHS 2019 - Nigeria	0.06	[0.05; 0.06]
MICS 2017 - Mauritania	0.04	[0.04; 0.05]
DHS 2012 - Burkina Faso	0.01	[0.01; 0.01]
MICS 2018 - Iraq	0.01	[0.01; 0.02]
Random effects model	**0.12**	**[0.07; 0.19]**

Heterogeneity: $I^2 = 100\%$, $\tau^2 = 1.7424$, $p = 0$

0.1 0.2 0.3 0.4 0.5 0.6 0.7